# EDGAR Filing Document

**Accession Number:** 0001708035
**File Stem:** 0001708035-25-000118
**Filing Date:** 2025-11
**Character Count:** 240828
**Document Hash:** 96f4c19dd7599d5da36ba7f75bf862fd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001708035-25-000118.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001708035-25-000118

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 101

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ecovyst Inc.
- **CENTRAL INDEX KEY:** 0001708035
- **STANDARD INDUSTRIAL CLASSIFICATION:** CHEMICALS & ALLIED PRODUCTS [2800]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 813406833
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38221
- **FILM NUMBER:** 251453724

**BUSINESS ADDRESS:**
- **STREET 1:** 600 LEE ROAD, SUITE 200
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** 484-617-1200

**MAIL ADDRESS:**
- **STREET 1:** 600 LEE ROAD, SUITE 200
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PQ Group Holdings Inc.
- **DATE OF NAME CHANGE:** 20170531

?xml version='1.0' encoding='ASCII'? ecvt-20250930

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

---

| | |
|:---|:---|
| **(Mark One)** | **(Mark One)** |
| ☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

**For the quarterly period ended September 30, 2025**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Commission File Number: 001-38221** 

**Ecovyst Inc.**

---

| | |
|:---|:---|
| **Delaware** | **81-3406833** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |
| **600 Lee Road, Suite 200** |  |
| **Wayne, Pennsylvania** | **19087** |
| (Address of principal executive offices) | (Zip Code) |
| **(484)** | **617-1200** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |
| **300 Lindenwood Drive, Malvern, Pennsylvania** | **300 Lindenwood Drive, Malvern, Pennsylvania** |
| (Former address, if changed since last report) | (Former address, if changed since last report) |

---

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol** | **Name of each exchange on which registered** |
| Common stock, par value $0.01 per share | ECVT | New York Stock Exchange |

---

------

---

| | | | |
|:---|:---|:---|:---|
| Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ |
| Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ |
| Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. | Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. | Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. | Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. |
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
| Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒ | Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒ | Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒ | Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒ |
| The number of shares of common stock outstanding as of October 29, 2025 was 114,019,414. | The number of shares of common stock outstanding as of October 29, 2025 was 114,019,414. | The number of shares of common stock outstanding as of October 29, 2025 was 114,019,414. | The number of shares of common stock outstanding as of October 29, 2025 was 114,019,414. |

---

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**Ecovyst Inc.**

**INDEX—FORM 10-Q**

**September 30, 2025**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **<u>[PART I](#iddb748d90dea449ba1f5857845b24cb5_10)</u>** | **<u>[FINANCIAL INFORMATION](#iddb748d90dea449ba1f5857845b24cb5_10)</u>** | |
| <u>[Item 1.](#iddb748d90dea449ba1f5857845b24cb5_13)</u> | <u>[Financial Statements (Unaudited)](#iddb748d90dea449ba1f5857845b24cb5_13)</u> |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of](#iddb748d90dea449ba1f5857845b24cb5_16)[(Loss)](#iddb748d90dea449ba1f5857845b24cb5_16)[Income](#iddb748d90dea449ba1f5857845b24cb5_16)</u> | <u>[4](#iddb748d90dea449ba1f5857845b24cb5_16)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive](#iddb748d90dea449ba1f5857845b24cb5_19)[(](#iddb748d90dea449ba1f5857845b24cb5_19)[Loss)](#iddb748d90dea449ba1f5857845b24cb5_19)[Income](#iddb748d90dea449ba1f5857845b24cb5_19)</u> | <u>[5](#iddb748d90dea449ba1f5857845b24cb5_19)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets](#iddb748d90dea449ba1f5857845b24cb5_22)</u> | <u>[6](#iddb748d90dea449ba1f5857845b24cb5_22)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Stockholders' Equity](#iddb748d90dea449ba1f5857845b24cb5_25)</u> | <u>[7](#iddb748d90dea449ba1f5857845b24cb5_25)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows](#iddb748d90dea449ba1f5857845b24cb5_28)</u> | <u>[9](#iddb748d90dea449ba1f5857845b24cb5_28)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements](#iddb748d90dea449ba1f5857845b24cb5_31)</u> | <u>[11](#iddb748d90dea449ba1f5857845b24cb5_31)</u> |
| <u>[Item 2.](#iddb748d90dea449ba1f5857845b24cb5_136)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#iddb748d90dea449ba1f5857845b24cb5_136)</u> | <u>[33](#iddb748d90dea449ba1f5857845b24cb5_136)</u> |
| <u>[Item 3.](#iddb748d90dea449ba1f5857845b24cb5_151)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#iddb748d90dea449ba1f5857845b24cb5_151)</u> | <u>[50](#iddb748d90dea449ba1f5857845b24cb5_151)</u> |
| <u>[Item 4.](#iddb748d90dea449ba1f5857845b24cb5_154)</u> | <u>[Controls and Procedures](#iddb748d90dea449ba1f5857845b24cb5_154)</u> | <u>[50](#iddb748d90dea449ba1f5857845b24cb5_154)</u> |
| **<u>[PART II](#iddb748d90dea449ba1f5857845b24cb5_157)</u>** | **<u>[OTHER INFORMATION](#iddb748d90dea449ba1f5857845b24cb5_157)</u>** |  |
| <u>[Item 1.](#iddb748d90dea449ba1f5857845b24cb5_160)</u> | <u>[Legal Proceedings](#iddb748d90dea449ba1f5857845b24cb5_160)</u> | <u>[51](#iddb748d90dea449ba1f5857845b24cb5_160)</u> |
| <u>[Item 1A.](#iddb748d90dea449ba1f5857845b24cb5_163)</u> | <u>[Risk Factors](#iddb748d90dea449ba1f5857845b24cb5_163)</u> | <u>[51](#iddb748d90dea449ba1f5857845b24cb5_163)</u> |
| <u>[Item 2.](#iddb748d90dea449ba1f5857845b24cb5_166)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#iddb748d90dea449ba1f5857845b24cb5_166)</u> | <u>[51](#iddb748d90dea449ba1f5857845b24cb5_166)</u> |
| <u>[Item 5.](#iddb748d90dea449ba1f5857845b24cb5_169)</u> | <u>[Other Information](#iddb748d90dea449ba1f5857845b24cb5_169)</u> | <u>[51](#iddb748d90dea449ba1f5857845b24cb5_169)</u> |
| <u>[Item 6.](#iddb748d90dea449ba1f5857845b24cb5_172)</u> | <u>[Exhibits](#iddb748d90dea449ba1f5857845b24cb5_172)</u> | <u>[52](#iddb748d90dea449ba1f5857845b24cb5_172)</u> |
|  | **<u>[SIGNATURES](#iddb748d90dea449ba1f5857845b24cb5_175)</u>** | <u>[53](#iddb748d90dea449ba1f5857845b24cb5_175)</u> |

---

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**PART I**—**FINANCIAL INFORMATION**

**ITEM 1. &nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS (UNAUDITED)**

**ECOVYST INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME**

**(in thousands, except share and per share amounts)**

**(unaudited)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** |
| Sales | $204907 | $153867 | $524082 | $449428 |
| Cost of goods sold | 152832 | 108732 | 412748 | 329032 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 52075 | 45135 | 111334 | 120396 |
| Selling, general and administrative expenses | 15658 | 15178 | 49768 | 49846 |
| Other operating expense, net | 8142 | 2414 | 18492 | 7859 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income | 28275 | 27543 | 43074 | 62691 |
| Interest expense, net | 8368 | 7912 | 24802 | 27068 |
| Debt modification and extinguishment costs |  |  | 960 | 4560 |
| Other (income) expense, net | (660) | 190 | (300) | 645 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from continuing operations before income taxes | 20567 | 19441 | 17612 | 30418 |
| Provision for income taxes | 20195 | 4602 | 19974 | 8029 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing operations | 372 | 14839 | (2362) | 22389 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income from discontinued operations, net of tax | (79627) | (588) | (74504) | 1378 |
| Net (loss) income | $(79255) | $14251 | $(76866) | $23767 |
| Net (loss) income per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic income (loss) per share - continuing operations | $— | $0.13 | $(0.02) | $0.19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted income (loss) per share - continuing operations | $— | $0.13 | $(0.02) | $0.19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic (loss) income per share - discontinued operations | $(0.70) | $(0.01) | $(0.64) | $0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted (loss) income per share - discontinued operations | $(0.69) | $(0.01) | $(0.64) | $0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic (loss) income per share | $(0.70) | $0.12 | $(0.66) | $0.20 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted (loss) income per share | $(0.69) | $0.12 | $(0.66) | $0.20 |
| Weighted average shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 113901834 | 116490634 | 115943873 | 116786759 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 114869273 | 117187054 | 115943873 | 117425254 |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME**

**(in thousands)** 

**(unaudited)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** |
| Net (loss) income | $(79255) | $14251 | $(76866) | $23767 |
| Other comprehensive (loss) income, net of tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and postretirement benefits | (1) | 3 | 169 | 527 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss from hedging activities | (1363) | (11654) | (8077) | (8865) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation | (1669) | 6403 | 11444 | 4040 |
| Total other comprehensive (loss) income | (3033) | (5248) | 3536 | (4298) |
| Comprehensive (loss) income | $(82288) | $9003 | $(73330) | $19469 |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands, except share and per share amounts)** 

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| ASSETS |  |  |
| Cash and cash equivalents | $81976 | $131390 |
| Accounts receivable, net | 83272 | 53204 |
| Inventories, net | 24134 | 17973 |
| Derivative assets | 2370 | 6532 |
| Prepaid and other current assets | 13495 | 10931 |
| Current assets held for sale | 91813 | 83684 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 297060 | 303714 |
| Property, plant and equipment, net | 481197 | 458684 |
| Goodwill | 326952 | 326589 |
| Other intangible assets, net | 62076 | 67700 |
| Right-of-use lease assets | 40535 | 33082 |
| Other long-term assets | 37904 | 37342 |
| Long-term assets held for sale | 489051 | 575210 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1734775 | $1802321 |
| LIABILITIES |  |  |
| Current maturities of long-term debt | $8730 | $8730 |
| Accounts payable | 47084 | 32936 |
| Operating lease liabilities—current | 9854 | 9053 |
| Accrued liabilities | 48714 | 39825 |
| Current liabilities held for sale | 17705 | 24582 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 132087 | 115126 |
| Long-term debt, excluding current portion | 846083 | 852099 |
| Deferred income taxes | 114429 | 105395 |
| Operating lease liabilities—noncurrent | 30850 | 23927 |
| Other long-term liabilities | 2809 | 3146 |
| Long-term liabilities held for sale | 651 | 2168 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 1126909 | 1101861 |
| Commitments and contingencies (Note 15) |  |  |
| EQUITY |  |  |
| Common stock ($0.01 par); authorized shares 450,000,000; issued shares 140,872,846 and 140,872,846 on September 30, 2025 and December 31, 2024, respectively; outstanding shares 114,019,414 and 116,534,803 on September 30, 2025 and December 31, 2024, respectively | 1409 | 1409 |
| Preferred stock ($0.01 par); authorized shares 50,000,000; no shares issued or outstanding on September 30, 2025 and December 31, 2024 |  |  |
| Additional paid-in capital | 1105604 | 1106792 |
| Accumulated deficit | (254374) | (177508) |
| Treasury stock, at cost; shares 26,853,432 and 24,338,043 on September 30, 2025 and December 31, 2024, respectively | (240902) | (222826) |
| Accumulated other comprehensive loss | (3871) | (7407) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 607866 | 700460 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $1734775 | $1802321 |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**-ECOVYST INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(in thousands)**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common <br>stock** | **Additional <br>paid-in <br>capital** | **Accumulated deficit** | **Treasury <br>stock, at <br>cost** | **Accumulated <br>other <br>comprehensive <br>loss** | **Total** |
| Balance, December 31, 2024 | $1409 | $1106792 | $(177508) | $(222826) | $(7407) | $700460 |
| &nbsp;&nbsp;&nbsp;Net loss |  |  | (3597) |  |  | (3597) |
| &nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  |  | 226 | 226 |
| &nbsp;&nbsp;&nbsp;Tax withholdings on equity award vesting |  |  |  | (1477) |  | (1477) |
| &nbsp;&nbsp;&nbsp;Stock compensation expense |  | 3072 |  |  |  | 3072 |
| &nbsp;&nbsp;&nbsp;Shares issued under equity incentive plan, net of forfeitures |  | (9519) |  | 9519 |  |  |
| Balance, March 31, 2025 | $1409 | $1100345 | $(181105) | $(214784) | $(7181) | $698684 |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 5986 |  |  | 5986 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  |  | 6343 | 6343 |
| &nbsp;&nbsp;&nbsp;Repurchases of common shares |  |  |  | (21917) |  | (21917) |
| &nbsp;&nbsp;&nbsp;Excise tax on repurchases of common shares |  |  |  | (151) |  | (151) |
| &nbsp;&nbsp;&nbsp;Stock compensation expense |  | 3395 |  |  |  | 3395 |
| &nbsp;&nbsp;&nbsp;Shares issued under equity incentive plan, net of forfeitures |  | (212) |  | 259 |  | 47 |
| Balance, June 30, 2025 | $1409 | $1103528 | $(175119) | $(236593) | $(838) | $692387 |
| &nbsp;&nbsp;&nbsp;Net loss |  |  | (79255) |  |  | (79255) |
| &nbsp;&nbsp;&nbsp;Other comprehensive loss |  |  |  |  | (3033) | (3033) |
| &nbsp;&nbsp;&nbsp;Repurchases of common shares |  |  |  | (5540) |  | (5540) |
| &nbsp;&nbsp;&nbsp;Excise tax on repurchases of common shares |  |  |  | (42) |  | (42) |
| &nbsp;&nbsp;&nbsp;Stock compensation expense |  | 2918 |  |  |  | 2918 |
| &nbsp;&nbsp;&nbsp;Shares issued under equity incentive plan, net of forfeitures |  | (842) |  | 1273 |  | 431 |
| Balance, September 30, 2025 | $1409 | $1105604 | $(254374) | $(240902) | $(3871) | $607866 |

---

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common <br>stock** | **Additional <br>paid-in <br>capital** | **Accumulated deficit** | **Treasury <br>stock, at <br>cost** | **Accumulated <br>other <br>comprehensive <br>(loss) income** | **Total** |
| Balance, December 31, 2023 | $1407 | $1102581 | $(170856) | $(226710) | $(958) | $705464 |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 1221 |  |  | 1221 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  |  | 2174 | 2174 |
| &nbsp;&nbsp;&nbsp;Tax withholdings on equity award vesting |  |  |  | (1218) |  | (1218) |
| &nbsp;&nbsp;&nbsp;Stock compensation expense |  | 3674 |  |  |  | 3674 |
| &nbsp;&nbsp;&nbsp;Shares issued under equity incentive plan, net of forfeitures | 2 | (9290) |  | 9329 |  | 41 |
| Balance, March 31, 2024 | $1409 | $1096965 | $(169635) | $(218599) | $1216 | $711356 |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 8295 |  |  | 8295 |
| &nbsp;&nbsp;&nbsp;Other comprehensive loss |  |  |  |  | (1224) | (1224) |
| &nbsp;&nbsp;&nbsp;Repurchases of common shares |  |  |  | (5010) |  | (5010) |
| &nbsp;&nbsp;&nbsp;Stock compensation expense |  | 3827 |  |  |  | 3827 |
| &nbsp;&nbsp;&nbsp;Shares issued under equity incentive plan, net of forfeitures |  | (43) |  | 82 |  | 39 |
| Balance, June 30, 2024 | $1409 | $1100749 | $(161340) | $(223527) | $(8) | $717283 |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 14251 |  |  | 14251 |
| &nbsp;&nbsp;&nbsp;Other comprehensive loss |  |  |  |  | (5248) | (5248) |
| &nbsp;&nbsp;&nbsp;Stock compensation expense |  | 2952 |  |  |  | 2952 |
| &nbsp;&nbsp;&nbsp;Shares issued under equity incentive plan, net of forfeitures |  | (340) |  | 472 |  | 132 |
| Balance, September 30, 2024 | $1409 | $1103361 | $(147089) | $(223055) | $(5256) | $729370 |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(in thousands)** 

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | $(76866) | $23767 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss (income) from discontinued operations | 74504 | (1378) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income from continuing operations | (2362) | 22389 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net (loss) income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 50002 | 44506 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization | 8014 | 8014 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred financing costs and original issue discount | 888 | 1082 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debt extinguishment costs |  | 90 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income tax provision (benefit) | 18940 | (3424) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset disposals | 4047 | 832 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock compensation | 7551 | 8291 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (7200) | (7894) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Working capital changes that provided (used) cash: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables | (20391) | 1304 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (3106) | (233) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaids and other current assets | 368 | (1109) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 14600 | (3855) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 6210 | (3998) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities, continuing operations | 77561 | 65995 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities, discontinued operations | 20986 | 40400 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 98547 | 106395 |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment | (51596) | (42961) |
| &nbsp;&nbsp;&nbsp;&nbsp;Business combinations | (41315) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities, continuing operations | (92911) | (42961) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities, discontinued operations | (15549) | (13264) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (108460) | (56225) |

---

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

---

| | | |
|:---|:---|:---|
| | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of long-term debt, net of original issue discount and financing fees | 870817 | 870817 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of long-term debt | (877365) | (877500) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchases of common shares | (27457) | (5010) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax withholdings on equity award vesting | (1477) | (1218) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 456 | 153 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities, continuing operations | (35026) | (12758) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities, discontinued operations | (2433) | (2354) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (37459) | (15112) |
| Effect of exchange rate changes on cash and cash equivalents | 467 | 51 |
| Net change in cash and cash equivalents | (46905) | 35109 |
| Cash and cash equivalents at beginning of period | 146013 | 88365 |
| Cash and cash equivalents at end of period | 99108 | 123474 |
| Less: cash, cash equivalents, and restricted cash of discontinued operations | (17132) | (23228) |
| Cash, cash equivalents and restricted cash at end of period of continuing operations | $81976 | $100246 |

---

For supplemental cash flow disclosures, see Note 19.

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**1. Background and Basis of Presentation:**

***Description of Business***

Ecovyst Inc. and subsidiaries (the "Company" or "Ecovyst") is a leading provider of virgin sulfuric acid and sulfuric acid regeneration services. The Company supports customers through its strategically located network of manufacturing facilities. The Company believes that its products and services contribute to improving the sustainability of the environment.

The Company has a uniquely positioned specialty business, Ecoservices, which provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides high quality and high strength virgin sulfuric acid for industrial and mining applications. Ecoservices also provides chemical waste handling and treatment services, as well as ex-situ catalyst activation services for the refining and petrochemical industry.

The Company's regeneration services product group typically experiences seasonal fluctuations as a result of higher demand for gasoline products in the summer months and lower demand in the winter months. These demand fluctuations result in higher sales and working capital requirements in the second and third quarters.

***Basis of Presentation***

The condensed consolidated financial statements included herein are unaudited. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States ("GAAP") have been condensed or omitted pursuant to such rules and regulations for interim reporting. In the opinion of management, all adjustments of a normal and recurring nature necessary to state fairly the financial position and results of operations have been included. The results of operations are not necessarily indicative of the expected results for the full year. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

On September 10, 2025, the Company entered into a definitive agreement to sell its Advanced Materials & Catalysts business for a purchase price of $556,000, subject to certain purchase price adjustments as set forth in the agreement. Upon entering into the definitive agreement, the transaction met the held for sale criteria under *ASC 360* and consequently the financial results of the Advanced Materials & Catalysts business are reported in discontinued operations in the condensed consolidated financial statements for all periods presented. See Note 3 for more information on this transaction.

The notes to the condensed consolidated financial statements, unless otherwise indicated, are on a continuing operations basis.

**2. New Accounting Standards:**

***Accounting Standards Recently Adopted***

In August 2023, the Financial Accounting Standards Board ("FASB") issued guidance for entities that meet the definition of a joint venture or a corporate joint venture, to adopt a new basis of accounting upon the formation of the joint venture. The new guidance requires the initial measurement of contributed net assets and liabilities at fair value on the formation date, recognition of goodwill for the difference between the fair value of the joint venture's equity and net assets, and disclosures about the nature and financial impact of the transaction. The new guidance requires prospective application and is effective for all joint ventures that are formed on or after January 1, 2025, with early adoption permitted. Joint ventures that formed before January 1, 2025 may elect to retrospectively apply the new guidance. The Company has adopted the new guidance as required on January 1, 2025 and will apply the guidance to any new joint ventures formed after the effective date.

In November 2023, FASB issued guidance to improve the disclosures related to public business entities ("PBEs") reportable segments. This new guidance requires entities to provide information regarding significant segment expenses, especially those segment expenses that are regularly reported to the Company's chief operating decision maker ("CODM," or the Company's Chief Executive Officer). The guidance also requires public entities to disclose the nature, type and amounts of other segment items by reportable segment. PBEs will also have to report all annual disclosures about segments profits or losses that are required by *ASC 280* on an interim basis, including the significant segment expenses and other segment items. The new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted the new guidance effective December 31, 2024.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

***Accounting Standards Not Yet Adopted***

In July 2025, FASB issued guidance related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under *ASC 606*. This new guidance introduces a practical expedient for entities that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. The new guidance is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of this guidance.

In November 2024, FASB issued guidance requiring PBEs to disclose additional information on the nature of certain expenses presented in the income statement. The new guidance requires tabular disclosure of significant expense categories and qualitative descriptions for amounts not disaggregated from relevant expense categories. PBEs are required to define selling expenses and disaggregate the components. The new guidance is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The requirements must be applied prospectively however PBEs have the option to apply the guidance retrospectively. The disclosure will be implemented as required for the fiscal year ended December 31, 2027. The Company is currently evaluating the impact of this guidance.

In December 2023, FASB issued guidance to improve disclosures related to incomes taxes. This new guidance requires PBEs to disaggregate information on the effective tax rate reconciliation and income taxes paid to provide greater transparency. PBEs will be required to provide additional information in specified categories related to effective tax rate reconciliation in tabular form and provide income taxes paid by jurisdictions, with further disaggregation needed if amounts exceed 5% of the total. The new guidance is effective for fiscal years beginning after December 15, 2024. The disclosure will be implemented as required for the fiscal year ended December 31, 2025. The Company is currently evaluating the impact of this guidance.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**3. Divestiture:**

***Advanced Materials & Catalysts Divestiture***

On September 10, 2025, the Company entered into a definitive agreement to sell its Advanced Materials & Catalysts business to Technip Energies N.V. for a purchase price of $556,000, subject to certain adjustments including for indebtedness, cash, working capital and transaction expenses, as set forth in the definitive agreement (the "Advanced Materials & Catalysts Sale"). The Advanced Materials & Catalysts Sale is expected to be completed in the first quarter of 2026, subject to regulatory approvals and customary closing conditions.

In the third quarter of 2025, the Advanced Materials & Catalysts business met the criteria set forth in *ASC 205-20*, as the sale represents a strategic shift that will have a major effect on the Company's operations and financial results. As a result, the Company's condensed consolidated financial statements for all periods presented reflect the Advanced Materials & Catalysts business as a discontinued operation. The Advanced Materials & Catalysts business historically represented a reportable segment of the Company.

As a result of the Advanced Materials & Catalysts business meeting held for sale criteria in the third quarter of 2025, the Company is required to measure the disposal group at the lower of its carrying values or fair values less costs to sell. As such, the Company performed an impairment analysis using a fair value estimate based on the agreed upon arm's length sales price resulting in the recognition of an impairment charge for assets classified as held for sale of $83,898 during the three months ended September 30, 2025. This impairment charge primarily consisted of a $49,636 impairment charge to goodwill along with a $34,262 valuation allowance on assets held for sale. The final fair value estimate at the completion of the sale could vary from the current fair value estimate. The Company's estimate of fair value will be evaluated and additional impairments or recoveries of amounts previously impaired may be recognized in future periods until the divestiture is complete.

The following table summarizes the results of discontinued operations related to the Advanced Materials & Catalysts business for the three and nine months ended September 30, 2025 and 2024, respectively:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Sales | $21609 | $25308 | $64760 | $73104 |
| Cost of goods sold | 14802 | 15740 | 41874 | 45911 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 6807 | 9568 | 22886 | 27193 |
| Selling, general and administrative expenses | 4471 | 4772 | 14367 | 14414 |
| Impairment of assets held for sale | 83898 |  | 83898 |  |
| Other operating expense, net | 4217 | 798 | 8298 | 2128 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating (loss) income | (85779) | 3998 | (83677) | 10651 |
| Equity in net (income) from affiliated companies | (2261) | 922 | (13104) | (2543) |
| Interest expense, net <sup>(1)</sup>  | 2801 | 3393 | 8494 | 10541 |
| Other (income) expense, net | (31) | 376 | 364 | 548 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income from discontinued operations before income taxes | (86288) | (693) | (79431) | 2105 |
| (Benefit) provision for income taxes | (6661) | (105) | (4927) | 727 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income from discontinued operations, net of tax | $(79627) | $(588) | $(74504) | $1378 |

---

<sup>(1)</sup> Upon the close of the Advanced Materials & Catalysts Sale and finalization of net cash proceeds, the Company will be required to provide partial repayment under its Term Loan Credit Agreement dated as of January 30, 2025 ("2025 Term Loan Facility"). As such, interest expense has been allocated to discontinued operations on the basis of the Company's estimated mandatory partial repayment of the 2025 Term Loan Facility.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The following table summarizes the assets and liabilities of discontinued operations related to the Advanced Materials & Catalysts divestiture as of September 30, 2025 and December 31, 2024, respectively:

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| ASSETS |  |  |
| Cash and cash equivalents | $17132 | $14623 |
| Accounts receivables, net | 20082 | 24733 |
| Inventories, net | 47190 | 39153 |
| Prepaid and other current assets | 7409 | 5175 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current assets held for sale | $91813 | $83684 |
| Investments in affiliated companies | $343783 | $349308 |
| Property, plant and equipment, net | 113254 | 110591 |
| Goodwill | 29687 | 77513 |
| Other intangible assets, net | 29036 | 30713 |
| Right-of-use lease assets | 830 | 476 |
| Other long-term assets | 6723 | 6609 |
| Valuation allowance on assets held for sale | (34262) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term assets held for sale | $489051 | $575210 |
| LIABILITIES |  |  |
| Accounts payable | $5300 | $10992 |
| Operating lease liabilities—current | 351 | 214 |
| Accrued liabilities | 12054 | 13376 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current liabilities held for sale | $17705 | $24582 |
| Deferred income taxes | $70 | $— |
| Operating lease liabilities—noncurrent | 479 | 262 |
| Other long-term liabilities | 102 | 1906 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term liabilities held for sale | $651 | $2168 |

---

The disposal group includes the Company's investment in an affiliated company, which was historically accounted for under the equity method. The following table provides summarized financial information of the combined investments in affiliated companies that were included within the divested business unit:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Sales | $79128 | $76568 | $237238 | $204073 |
| Gross profit | 16180 | 9200 | 58132 | 43129 |
| Operating income (loss) | 5803 | (1608) | 28053 | 10976 |
| Net income (loss) | 5463 | (623) | 29190 | 11387 |

---

Certain administrative services are provided to the affiliated company by the Company. The Company charged $576 and $1,728 for the three and nine months ended September 30, 2025 and $687 and $2,062 for the three and nine months ended September 30, 2024, respectively, which were included in selling, general and administrative expenses in the condensed consolidated statements of (loss) income.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**4. Revenue from Contracts with Customers:**

***Disaggregated Revenue***

The Company's primary means of disaggregating revenue is by key end uses, which are described in the table below.

---

| | |
|:---|:---|
| **Key End Uses** | **Key Products** |
| Regeneration and treatment services | • Sulfuric acid regeneration services |
| | • Hazardous waste treatment services |
| Industrial, mining & automotive | • Virgin sulfuric acid for mining |
| | • Virgin sulfuric acid derivatives for industrial production |
| | • Virgin sulfuric acid derivatives for nylon production |
| Other | • Catalyst activation |
| | • Aluminum sulfate solution |
| | • Ammonium bisulfite solution |

---

The following table disaggregates the Company's sales by key end uses, for the three and nine months ended September 30, 2025 and 2024, respectively:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Regeneration and treatment services<sup>(1)</sup> | $99157 | $91037 | $271192 | $269721 |
| Industrial, mining & automotive | 96430 | 53291 | 226641 | 154165 |
| Other | 9320 | 9539 | 26249 | 25542 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total sales | $204907 | $153867 | $524082 | $449428 |

---

<sup>(1)</sup> As described in Note 1 to these condensed consolidated financial statements, the Company experiences seasonal sales fluctuations to customers in the regeneration services product group.

**5. Fair Value Measurements:**

Fair values are based on quoted market prices when available. When market prices are not available, fair values are generally estimated using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality. In instances where there is little or no market activity for the same or similar instruments, the Company estimates fair values using methods, models and assumptions that management believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of management estimation and judgment that becomes significant with increasingly complex instruments or pricing models. Where appropriate, adjustments are included to reflect the risk inherent in a particular methodology, model or input used.

The Company's financial assets and liabilities carried at fair value have been classified based upon a fair value hierarchy. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). The classification of an asset or a liability is based on the lowest level input that is significant to its measurement. For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). The levels of the fair value hierarchy are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1—Values are unadjusted quoted prices for identical assets and liabilities in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2—Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are observable or can be corroborated by market data for the term of the instrument. Such inputs include market interest rates and volatilities, spreads and yield curves.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3—Certain inputs are unobservable (supported by little or no market activity) and significant to the fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date.

***Fair value on a recurring basis***

The following tables present information about the Company's assets and liabilities that were measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **September 30,<br>2025** | **Quoted Prices in <br>Active Markets <br>(Level 1)** | **Significant Other Observable Inputs (Level 2)** | **Significant <br>Unobservable Inputs <br>(Level 3)** |
| Derivative assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps (Note 12) | $2510 | $— | $2510 | $— |
| Derivative liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps (Note 12) | $1569 | $— | $1569 | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31,<br>2024** | **Quoted Prices in <br>Active Markets <br>(Level 1)** | **Significant Other Observable Inputs (Level 2)** | **Significant <br>Unobservable Inputs <br>(Level 3)** |
| Derivative assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps (Note 12) | $12500 | $— | $12500 | $— |
| Derivative liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps (Note 12) | $710 | $— | $710 | $— |

---

*Derivative contracts*

Derivative assets and liabilities can be exchange-traded or traded over-the-counter ("OTC"). The Company generally values exchange-traded derivatives using models that calibrate to market transactions and eliminate timing differences between the closing price of the exchange-traded derivatives and their underlying instruments. OTC derivatives are valued using market transactions and other market evidence whenever possible, including market-based inputs to models, model calibration to market transactions, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. When models are used, the selection of a particular model to value an OTC derivative depends on the contractual terms of, and specific risks inherent in, the instrument as well as the availability of pricing information in the market. The Company generally uses similar models to value similar instruments. Valuation models require a variety of inputs, including contractual terms, market prices and rates, forward curves, measures of volatility, and correlations of such inputs. For OTC derivatives that trade in liquid markets, such as forward contracts, swaps and options, model inputs can generally be corroborated by observable market data by correlation or other means, and model selection does not involve significant management judgment.

As of September 30, 2025, the Company had interest rate caps that were fair valued using Level 2 inputs. In addition, the Company applies a credit valuation adjustment to reflect credit risk which is calculated based on credit default swaps. To the extent that the Company's net exposure under a specific master agreement is an asset, the Company utilizes the counterparty's default swap rate. If the net exposure under a specific master agreement is a liability, the Company utilizes a default swap rate comparable to Ecovyst. The credit valuation adjustment is added to the discounted fair value to reflect the exit price that a market participant would be willing to receive to assume the Company's liabilities or that a market participant would be willing to pay for the Company's assets.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**6. Stockholders' Equity:**

***Accumulated Other Comprehensive Loss***

The following tables present the tax effects of each component of other comprehensive (loss) income for the three and nine months ended September 30, 2025 and 2024, respectively:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** |
| | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
| | **Pre-tax amount** | **Tax benefit/(expense)** | **After-tax amount** | **Pre-tax amount** | **Tax benefit/(expense)** | **After-tax amount** |
| Defined benefit and other postretirement plans: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) gain | $(1) | $— | $(1) | $11 | $(3) | $8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net prior service cost |  |  |  | (7) | 2 | (5) |
| Benefit plans, net | (1) |  | (1) | 4 | (1) | 3 |
| Net loss from hedging activities | (1817) | 454 | (1363) | (15539) | 3885 | (11654) |
| Foreign currency translation | (1669) |  | (1669) | 6403 |  | 6403 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive loss | $(3487) | $454 | $(3033) | $(9132) | $3884 | $(5248) |
|  | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|  | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
|  | **Pre-tax<br>amount** | **Tax benefit/<br>(expense)** | **After-tax amount** | **Pre-tax<br>amount** | **Tax benefit/<br>(expense)** | **After-tax amount** |
| Defined benefit and other postretirement plans: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net gain | $224 | $(55) | $169 | $724 | $(181) | $543 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net prior service cost |  |  |  | (22) | 6 | (16) |
| Benefit plans, net | 224 | (55) | 169 | 702 | (175) | 527 |
| Net loss from hedging activities | (10769) | 2692 | (8077) | (11820) | 2955 | (8865) |
| Foreign currency translation | 11444 |  | 11444 | 4040 |  | 4040 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) | $899 | $2637 | $3536 | $(7078) | $2780 | $(4298) |

---

The following tables present the changes in accumulated other comprehensive loss ("AOCI"), net of tax, by component for the nine months ended September 30, 2025 and 2024, respectively:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Defined benefit <br>and other <br>postretirement <br>plans** | **Net gain (loss) from hedging activities** | **Foreign <br>currency <br>translation** | **Total** |
| December 31, 2024 | $1467 | $9902 | $(18776) | $(7407) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 172 | (3378) | 11444 | 8238 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from AOCI<sup>(1)</sup> | (3) | (4699) |  | (4702) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net current period other comprehensive income (loss) | 169 | (8077) | 11444 | 3536 |
| September 30, 2025 | $1636 | $1825 | $(7332) | $(3871) |
| December 31, 2023 | $612 | $12546 | $(14116) | $(958) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income before reclassifications | 549 | 1657 | 4040 | 6246 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from AOCI<sup>(1)</sup> | (22) | (10522) |  | (10544) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net current period other comprehensive income (loss) | 527 | (8865) | 4040 | (4298) |
| September 30, 2024 | $1139 | $3681 | $(10076) | $(5256) |

---

<sup>(1)</sup> See the following table for details about these reclassifications. Amounts in parentheses indicate debits.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The following table presents the reclassifications out of AOCI for the three and nine months ended September 30, 2025 and 2024, respectively:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Details about AOCI Components** | **Amounts reclassified from AOCI**<sup>(1)</sup> | **Amounts reclassified from AOCI**<sup>(1)</sup> | **Amounts reclassified from AOCI**<sup>(1)</sup> | **Amounts reclassified from AOCI**<sup>(1)</sup> | **Affected line item where <br>income is presented** |
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** | |
|  | **2025** | **2024** | **2025** | **2024** |  |
| Amortization of defined benefit and other postretirement items: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $1 | $— | $4 | $7 | Other expense<sup>(2)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net prior service cost |  | 7 |  | 22 | Other expense<sup>(2)</sup> |
|  | 1 | 7 | 4 | 29 | Total before tax |
|  |  | (2) | (1) | (7) | Tax benefit |
|  | $1 | $5 | $3 | $22 | Net of tax |
| Gains and losses on cash flow hedges: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | $2041 | $4711 | $6266 | $14029 | Interest expense |
|  | (510) | (1177) | (1567) | (3507) | Tax benefit |
|  | $1531 | $3534 | $4699 | $10522 | Net of tax |
| Total reclassifications for the period | $1532 | $3539 | $4702 | $10544 | Net of tax |

---

<sup>(1)</sup> Amounts in parentheses indicate debits to profit/loss.

<sup>(2)</sup> These AOCI components are components of net periodic pension and other postretirement cost (see Note 14 to these condensed consolidated financial statements for additional details).

***Treasury Stock Repurchases***

*2022 Stock Repurchase Program*

On April 27, 2022, the Company's board of directors (the "Board") approved a stock repurchase program that authorized the Company to purchase up to $450,000 of the Company's common stock over the four-year period from the date of approval (the "Stock Repurchase Program"). On October 30, 2025, the Board amended the Stock Repurchase Program to remove the limitation that all repurchases must be made within the four-year period from the date of original approval. Under the plan, the Company is permitted to repurchase shares from time to time for cash in open market transactions or in privately negotiated transactions in accordance with applicable federal securities laws, with the Company determining the timing and the amount of any repurchases based on its evaluation of market conditions, share price and other factors.

During the nine months ended September 30, 2025, the Company repurchased 3,536,364 shares on the open market at an average price of $7.74 per share, for a total of $27,387, excluding brokerage commissions and accrued excise tax. During the nine months ended September 30, 2025, the Company accrued $193 of excise tax related to these repurchases, net of shares issued under the Company's equity incentive program (see Note 17 to these condensed consolidated financial statements). As of September 30, 2025, $202,207 was available for share repurchases under the program.

During the nine months ended September 30, 2024, the Company repurchased 552,081 shares on the open market at an average price of $9.05 per share, for a total of $4,998, excluding brokerage commissions and accrued excise tax. During the nine months ended September 30, 2024, the Company did not need to accrue excise tax related to these repurchases, net of shares issued under the Company's equity incentive program (see Note 17 to these condensed consolidated financial statements).

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

*Tax Withholdings on Equity Award Vesting*

In connection with the vesting of restricted stock awards ("RSA" or "RSAs"), restricted stock units ("RSU" or "RSUs") and performance stock units ("PSU" or "PSUs"), shares of common stock may be delivered to the Company by employees to satisfy withholding tax obligations at the instruction of the employee award holders. These transactions, when they occur, are accounted for as stock repurchases by the Company, with the shares returned to treasury stock at a cost representing the payment by the Company of the tax obligations on behalf of the employees in lieu of shares for the vesting event. There were 189,446 and 128,801 shares delivered to the Company to cover tax payments for the nine months ended September 30, 2025 and 2024, respectively, and the fair value of those shares withheld were $1,477 and $1,218 for the nine months ended September 30, 2025 and 2024, respectively.

**7. Goodwill:**

The following table provides a summary of the changes in the carrying amount of goodwill associated with the Ecoservices segment for the nine months ended September 30, 2025:

---

| | |
|:---|:---|
| Balance as of December 31, 2024 | $326589 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill recognized (Note 8) | 363 |
| Balance as of September 30, 2025 | $326952 |

---

The Company completes its annual goodwill and indefinite-lived intangible assets impairment test during the fourth quarter of each year, or more frequently if triggering events indicate a possible impairment. The Company determined the fair value of its reporting unit using both a market approach and an income, or discounted cash flow, approach. As of October 1, 2024, the date of the Company's most recent quantitative assessments, the fair value of the Company's reporting unit and the fair value of the Company's indefinite-lived trade names and trademarks exceeded their respective carrying values.

During the nine months ended September 30, 2025, the Company did not identify any events or circumstances that would more likely than not reduce the fair value of the Company's reporting unit below its carrying value.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**8. Acquisition:**

On May 6, 2025 (the "Closing Date"), the Company completed its acquisition of the sulfuric acid production assets of Cornerstone Chemical Company LLC ("Cornerstone") located in Waggaman, Louisiana. As part of an asset purchase agreement (the "Acquisition"), the Company paid $41,315 in cash, consisting of the $35,000 purchase price plus $6,315 of adjustments for working capital, pursuant to the agreement. The sulfuric acid production assets will be used to increase capacity of virgin sulfuric acid and sulfuric acid regeneration services to current and future customers.

The Acquisition is a business combination, therefore the acquisition method was applied. Under the acquisition method, the purchase price was allocated to the identifiable assets acquired based on the fair values of the identifiable assets acquired as of the Closing Date. The excess of the purchase price over fair values of the identifiable assets acquired was recorded to goodwill.

The table below presents the provisional fair values allocated to the assets acquired. The purchase accounting and purchase price allocation for Cornerstone are preliminary and the Company continues to refine the preliminary valuation of certain acquired assets which could impact the amount of residual goodwill recorded. The Company intends to finalize the amounts recognized as it obtains the information necessary to complete the analysis, but no later than one year from the date of the acquisition. Final determination of the fair values may result in further adjustments to the values presented in the following table:

---

| | |
|:---|:---|
| | **Preliminary Purchase<br>Price Allocation** |
| Cash paid | $41315 |
| Recognized amounts of identifiable assets acquired: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | $9812 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 3055 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment | 25000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets | 2390 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | 695 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of identifiable assets acquired | 40952 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 363 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets acquired | $41315 |

---

Adjustments to the preliminary amounts during the measurement period that result in changes to depreciation, amortization or other income effects will be recognized in the reporting period(s) in which the adjustments are determined.

In accordance with the requirements of the purchase method of accounting for acquisitions, accounts receivable and inventories were recorded at fair market value. As of the Closing Date, the fair value of accounts receivable approximated historical cost. The gross contractual amount of accounts receivable at the Closing Date was $9,812, of which there was no amount deemed uncollectible. Fair value of inventory is defined as estimated selling prices less the sum of (a) costs of disposal and (b) a reasonable profit allowance for the selling effort of the acquiring entity.

Prior to the acquisition, the Company had a preexisting relationship with Cornerstone. The Company had a net payable of $619 for a sulfuric acid exchange balance. As part of the acquisition terms, the payable was settled at cost, which was recorded separate from the business combination.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The valuation of intangibles assets acquired and the related weighted-average amortization period are as follows:

---

| | | |
|:---|:---|:---|
| | **Amount** | **Weighted-Average<br>Expected Useful Life<br>(in years)** |
| Intangible assets subject to amortization: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | $2390 | 15 |

---

The Company evaluated the disclosure requirements under *ASC 805* and determined the Acquisition was not considered a material business combination for purposes of disclosing the sales and earnings attributable to Cornerstone since the date of acquisition or supplemental pro forma information. Acquisition and integration costs were $1,315 and $4,070 for the three and nine months ended September 30, 2025, respectively, and are included in other operating expense, net in the Company's condensed consolidated statements of (loss) income.

The Company entered into an agreement with Cornerstone to lease the land where the acquired assets are located for a 7-year term plus renewal options. Additionally, Cornerstone will charge the Company for site services and utilities for the location.

**9. Other Operating Expense, Net:**

A summary of other operating expense, net is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Amortization expense | $2130 | $2130 | $6390 | $6390 |
| Transaction and other related costs | 554 |  | 2845 | 198 |
| Restructuring, integration and business optimization costs | 1764 | 58 | 2931 | 232 |
| Net loss on asset disposals | 3630 | 218 | 4047 | 832 |
| Other, net | 64 | 8 | 2279 | 207 |
| &nbsp;&nbsp;&nbsp;Total other operating expense, net | $8142 | $2414 | $18492 | $7859 |

---

**10. Inventories, Net:**

Inventories, net are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out ("FIFO") or average cost method. The components of inventories, net consist of the following:

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Finished products and work in process | $19703 | $15810 |
| Raw materials | 4431 | 2163 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total inventories, net | $24134 | $17973 |

---

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**11. Long-term Debt:**

The summary of long-term debt is as follows:

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| 2025 Term Loan Facility | $864271 | $870817 |
| ABL Facility |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total debt | 864271 | 870817 |
| Original issue discount | (6484) | (7201) |
| Deferred financing costs | (2974) | (2787) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total debt, net of original issue discount and deferred financing costs | 854813 | 860829 |
| Less: current portion | (8730) | (8730) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt, excluding current portion | $846083 | $852099 |

---

***Term Loan Facility***

In June 2024, the Company amended its Term Loan Credit Agreement dated as of June 9, 2021 to, among other things, (a) reduce the interest rate applicable to all outstanding Secured Overnight Financing Rate ("SOFR") term loans to a rate equal to the forward-looking term rate based on SOFR as administered by the Federal Reserve Bank of New York ("Term SOFR") plus 2.25% per annum from a maximum of adjusted Term SOFR plus 2.75% per annum, (b) reduce the interest rate applicable to all outstanding base rate term loans to the alternate base rate plus 1.25% per annum from a maximum of the alternate base rate plus 1.75% per annum and (c) extend the maturity date of all outstanding term loans to June 12, 2031. As a result of the amendment, there is no longer a credit spread adjustment of 10 basis points.

In January 2025, the Company amended its Term Loan Credit Agreement dated as of June 12, 2024 to, among other things, (a) reduce the interest rate applicable to all outstanding SOFR term loans to Term SOFR plus 2.00% per annum from a maximum of Term SOFR plus 2.25% per annum and (b) reduce the interest rate applicable to all outstanding base rate term loans to the alternate base rate plus 1.00% per annum from a maximum of the alternate base rate plus 1.25% per annum.

The Company evaluated the terms of the amendments in accordance with *ASC 470-50 Debt - Modification and Extinguishment* and determined that both amendments were a modification of debt. As a result of the January 2025 amendment, the Company recorded $960 of third-party financing costs within debt modification and extinguishment costs in the condensed consolidated statements of (loss) income for the nine months ended September 30, 2025. No third-party financing costs were recorded for the three months ended September 30, 2025, and no original issue discount was paid for the three and nine months ended September 30, 2025. As a result of the June 2024 amendment, the Company recorded $4,471 of third-party financing costs within debt modification and extinguishment costs in the condensed consolidated statements of (loss) income for the nine months ended September 30, 2024 and capitalized $2,183 of original issued discount within long-term debt, excluding current portion in the condensed consolidated balance sheets during the quarter ended June 30, 2024. In addition, $90 of previous unamortized deferred financing costs and original issue discount associated with the previously outstanding debt were written off as debt modification and extinguishment costs for the nine months ended September 30, 2024. No third-party financing costs were recorded for the three months ended September 30, 2024, and no original issue discount was paid for the three months ended September 30, 2024.

The interest rate on the 2025 Term Loan Facility was 5.98% as of September 30, 2025.

***ABL Facility***

The borrowings under the senior secured asset-based lending revolving credit facility ("ABL Facility") bear interest at a rate equal to an adjusted Term SOFR or the base rate plus a margin of between 1.25% to 1.75% or 0.25% to 0.75%, respectively. The interest rate on the ABL Facility was 7.50% as of September 30, 2025.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

In April 2025, the Company amended its ABL credit agreement ("ABL Credit Agreement") to, among other things, (a) reallocate all European revolving loan commitments thereunder as United States revolving loan commitments, (b) extend the maturity date with respect to borrowings under the ABL Credit Agreement by over three years to April 10, 2030 (subject to acceleration under certain circumstances), (c) reduce the interest rate applicable to outstanding revolving loans that bear interest at a rate equal to Term SOFR by removing the credit spread adjustment that was applied to Term SOFR in the ABL Credit Agreement in calculating adjusted Term SOFR, and (d) reduce the frequency of borrowing base reporting, field examinations and appraisals (subject to higher frequency under certain circumstances). As a result of the amendment, the Company capitalized $551 of deferred financing costs within long-term debt, excluding current portion in the condensed consolidated balance sheets during the quarter ended June 30, 2025.

***Fair Value of Debt***

The fair value of a financial instrument is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. As of September 30, 2025 and December 31, 2024, the fair value of the Company's term loan facility was $862,109 and $874,083, respectively. The fair value is classified as Level 2 based upon the fair value hierarchy (see Note 5 to these condensed consolidated financial statements for further information on fair value measurements).

**12. Financial Instruments:**

The Company uses interest rate related derivative instruments to manage its exposure to changes in interest rates on its variable-rate debt instruments. The Company does not speculate using derivative instruments.

By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is an asset, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is a liability, the Company owes the counterparty and therefore, the Company is not exposed to the counterparty's credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with high quality counterparties. The derivative instruments entered into by the Company do not contain credit-risk-related contingent features.

Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with the Company's derivative instruments is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken.

*Use of Derivative Financial Instruments to Manage Interest Rate Risk*

The Company is exposed to fluctuations in interest rates on its senior secured credit facilities. Changes in interest rates will not affect the market value of such debt but will affect the Company's interest payments over the term of the loans. Likewise, an increase in interest rates could have a material impact on the Company's condensed consolidated statements of cash flows. The Company hedges the interest rate fluctuations on debt obligations through interest rate cap agreements. The Company records these agreements at fair value as assets or liabilities in the condensed consolidated balance sheets. As the derivatives are designated and qualify as cash flow hedges, the gains or losses on the interest rate cap agreements are recorded in stockholders' equity as a component of other comprehensive (loss) income, net of tax. Reclassifications of the gains and losses on the interest rate cap agreements into earnings are recorded as part of interest expense in the condensed consolidated statements of (loss) income as the Company makes its interest payments on the hedged portion of its senior secured credit facilities. Fair value is determined based on estimated amounts that would be received or paid to terminate the contracts at the reporting date based on quoted market prices.

The following table provides a summary of the Company's interest rate cap agreements:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Financial instrument** | **Number of instruments** | **In effect as of September 30, 2025** | **Current notional amount of instruments in effect** | **Annuitized premium of instruments in effect** | **Cap rate in effect for all agreements at September 30, 2025** |
| Interest rate caps | 4 | 3 | $625000 | $35285 | 1.00% |

---

The current notional amounts of the three interest rate cap agreements in effect at September 30, 2025 are $250,000, $175,000 and $200,000. The Company entered into a $250,000 interest rate cap to mitigate interest rate volatility from September 2023 to October 2025, a $175,000 interest rate cap agreement to mitigate interest rate volatility from August 2024 to July 2026 and a $200,000 interest rate cap agreement to mitigate interest rate volatility from November 2024 to October 2025. The $200,000 interest rate cap agreement will increase to $450,000 to mitigate interest rate volatility from November 2025 to October 2026.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

During the quarter ended September 30, 2025, the Company dedesignated a portion of its interest rate caps. With the Company's expected prepayments on the 2025 Term Loan Facility (see Note 3 to these condensed consolidated financial statements for additional information), an estimated portion of the original forecasted interest rate payments associated with the dedesignated portion of the interest rate cap agreement may no longer be highly probable of occurring but continue to be reasonably possible of occurring. The Company will continue to amortize the loss into interest expense as long as the hedged transaction continues to be reasonably possible of occurring. If the hedged transaction is determined to be probable of not occurring, any remaining loss in AOCI will be immediately reclassified into earnings. The loss related to this portion is not material. Any future gains and losses associated with the dedesignated portion of the interest rate cap agreement through its maturity in October 2026 will be recognized in earnings.

The Company also entered into a $200,000 forward starting interest rate cap agreement to mitigate interest volatility from August 2026 to July 2028.

The fair values of derivative instruments held as of September 30, 2025 and December 31, 2024, respectively, are shown below:

---

| | | | |
|:---|:---|:---|:---|
| | **Balance sheet location** | **September 30,<br>2025** | **December 31,<br>2024** |
| *Derivative assets* |  |  |  |
| Derivatives designated as cash flow hedges: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Prepaid and other current assets | $1142 | $6532 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Other long-term assets | 48 | 5968 |
|  |  | 1190 | 12500 |
| Derivative not designated as hedging instrument: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Prepaid and other current assets | 1228 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Other long-term assets | 92 |  |
| Total derivative assets |  | $2510 | $12500 |
| *Derivative liabilities* |  |  |  |
| Derivatives designated as cash flow hedges: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Accrued liabilities | $949 | $235 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Other long-term liabilities | 620 | 475 |
| Total derivative liabilities |  | $1569 | $710 |

---

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The following tables show the effect of the Company's derivative instruments designated as cash flow hedges on AOCI and the condensed consolidated statements of (loss) income for the three and nine months ended September 30, 2025 and 2024, respectively:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Amount of gain (loss) recognized in OCI** | **Amount of gain (loss) recognized in OCI** | **Amount of gain (loss) recognized in OCI** | **Amount of gain (loss) recognized in OCI** |
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | $224 | $(10828) | $(4503) | $2209 |
|  | **Amount of loss reclassified from AOCI** | **Amount of loss reclassified from AOCI** | **Amount of loss reclassified from AOCI** | **Amount of loss reclassified from AOCI** |
|  | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | $(2041) | $(4711) | $(6266) | $(14029) |
|  | **Amount of loss reclassified into income** | **Amount of loss reclassified into income** | **Amount of loss reclassified into income** | **Amount of loss reclassified into income** |
|  | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | $2041 | $4711 | $6266 | $14029 |

---

The following table shows the amounts in the line items presented in the condensed consolidated statements of (loss) income in which the effects of derivatives designated as cash flow hedges are recorded for the three and nine months ended September 30, 2025 and 2024, respectively:

---

| | | | |
|:---|:---|:---|:---|
| | | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** |
| |<br>**Location and amount of gain (loss) recognized in income on cash flow hedging relationships** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Interest expense | $(8368) | $(7912) |
|  |  | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
|  |  | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Interest expense | $(24802) | $(27068) |

---

The amount of net unrealized gains in AOCI related to the Company's cash flow hedges that is expected to be reclassified to the condensed consolidated statements of (loss) income over the next twelve months is $2,489 as of September 30, 2025.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**13. Income Taxes:**

The effective income tax rate for the three months ended September 30, 2025 was 98.2%, compared to 23.7% for the three months ended September 30, 2024. The effective income tax rate for the nine months ended September 30, 2025 was 113.4%, compared to 26.4% for the nine months ended September 30, 2024. The Company's effective income tax rates for the three and nine months ended September 30, 2025 and 2024, respectively, fluctuated primarily due to the increased discrete tax impact relative to pre-tax book income related to a stock compensation shortfall, intraperiod allocation revaluation of deferred tax assets and liabilities including valuation allowances as a result of the Advanced Materials & Catalysts divestiture, state tax refunds associated with prior tax years and expense related to accrued penalties and interest on historical uncertain tax positions.

The tax expense for the three and nine months ended September 30, 2025 includes a $15,620 discrete tax expense connected to intraperiod allocation associated with the revaluation of deferred tax assets and liabilities, a valuation allowance against the Company's Kansas Investment Tax Credits, and an increase in valuation allowance against a portion of the Company's state net operating losses. In accordance with intraperiod allocation rules, this discrete tax expense is reflected in the tax provision for continuing operations.

The difference between the U.S. federal statutory income tax rate and the Company's effective income tax rate for the nine months ended September 30, 2025 was mainly due to state and local taxes, a shortfall tax expense related to stock compensation, tax benefit related to state tax refunds associated with prior tax years, discrete tax expense related to intraperiod allocation associated with the revaluation of deferred tax assets and liabilities, a valuation allowance against the Company's Kansas Investment Tax Credits, and a valuation allowance against a portion of the Company's state net operating losses.

The difference between the U.S. federal statutory income tax rate and the Company's effective income tax rate for the nine months ended September 30, 2024 was mainly due to state and local taxes, a discrete shortfall tax expense related to stock compensation and a discrete tax expense associated with the recording of accrued penalties and interest on historical uncertain tax positions.

During the three months ended September 30, 2025, the Company reassessed its indefinite reinvestment assertion with respect to its foreign subsidiaries as a result of the decision to divest the Advanced Materials & Catalysts business, which is now classified as held for sale. The Company no longer considers the undistributed earnings of its foreign subsidiaries to be permanently reinvested in non-U.S. operations. Accordingly, the Company considered the deferred tax impacts of the repatriation of the undistributed earnings of its foreign subsidiaries and concluded that there was no net tax impact necessary based on available information. The Company recorded a full valuation allowance offsetting a potential deferred tax asset for the excess of tax basis over the book basis of the foreign subsidiaries. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all the deferred tax assets will not be realized. We may release all or a portion of the valuation allowance in the near-term; however, the release of the valuation allowance will be evaluated at each reporting period until the divestiture is complete.

On July 4, 2025, H.R.1, the One Big Beautiful Bill Act ("OBBBA"), was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We do not expect the OBBBA to have a material impact on our estimated annual effective tax rate in 2025.

**14. Benefit Plans:**

The following tables present the components of net periodic expense (benefit) for the Company-sponsored defined benefit pension and postretirement plans, which cover certain employees and retirees located in the U.S.:

*Defined Benefit Pension Plans*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Interest cost | $818 | $807 | $2460 | $2421 |
| Expected return on plan assets | (809) | (837) | (2426) | (2511) |
| Settlement gain |  |  | (1) | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net periodic expense (benefit) | $9 | $(30) | $33 | $(96) |

---

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

*Other Postretirement Benefit Plan*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Interest cost | $6 | $6 | $19 | $18 |
| Amortization of prior service credit |  | (7) |  | (22) |
| Amortization of net gain | (1) |  | (3) | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net periodic expense (benefit) | $5 | $(1) | $16 | $(5) |

---

All components of net periodic expense (benefit) are presented within other (income) expense, net in the Company's condensed consolidated statements of (loss) income.

**15. Commitments and Contingent Liabilities:**

There is a risk of environmental impact in the Company's manufacturing operations. The Company's environmental policies and practices are designed to comply with existing laws and regulations and to minimize the possibility of significant environmental impact. The Company is also subject to various other lawsuits and claims with respect to matters such as governmental regulations, labor and other actions arising out of the normal course of business. All claims that are probable and reasonably estimable have been accrued for in the Company's condensed consolidated financial statements. When these matters are ultimately concluded and determined, the Company believes that there will be no material adverse effect on its condensed consolidated financial position, results of operations or liquidity.

**16. Segment Information:**

The segment information herein excludes the results of the Advanced Materials & Catalysts segment, which is reflected in held for sale and discontinued operations as described in Note 3, for all periods presented. The Company's CODM evaluates the operating results of the segments based upon Adjusted EBITDA. The CODM uses Adjusted EBITDA to allocate resources in the annual budget and forecasting process. The CODM considers budget-to-actual variances on a monthly basis when making decisions about allocating capital and personnel to the segments. The CODM also uses segment Adjusted EBITDA to evaluate the return on assets in connection with performance evaluation and to inform the compensation for certain employees.

Summarized financial information for the Company's Ecoservices reportable segment is shown in the following table:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Sales | $204907 | $153867 | $524082 | $449428 |
| Adjusted EBITDA <sup>(1)</sup> | $63631 | $55098 | $141928 | $146301 |

---

<sup>(1)</sup> The Company defines Adjusted EBITDA as EBITDA adjusted for certain items as noted in the reconciliation below. Management evaluates the performance and allocates resources based on several factors, of which the primary measure is Adjusted EBITDA. Adjusted EBITDA should not be considered as an alternative to net income (loss) from continuing operations as an indicator of the Company's operating performance. Adjusted EBITDA as defined by the Company may not be comparable with EBITDA or Adjusted EBITDA as defined by other companies.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The following table presents selected financial information with respect to the Company's Ecoservices reportable segment:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Sales | $204907 | $153867 | $524082 | $449428 |
| Less:<sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | $134628 | $92619 | $362083 | $283589 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 6652 | 6155 | 19864 | 19541 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other segment items | (4) | (5) | 207 | (3) |
| Adjusted EBITDA from the Ecoservices segment | $63631 | $55098 | $141928 | $146301 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 8368 | 7912 | 24802 | 27068 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 20668 | 18488 | 58016 | 52520 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unallocated corporate expenses | 6157 | 6445 | 21170 | 21394 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt modification and extinguishment costs |  |  | 960 | 4560 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset disposals | 3630 | 218 | 4047 | 832 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction and other related costs | 554 |  | 2845 | 198 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 2271 | 2348 | 7551 | 8291 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring, integration and business optimization expenses | 1764 | 58 | 2931 | 232 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (348) | 188 | 1994 | 788 |
| Income from continuing operations before income taxes | $20567 | $19441 | $17612 | $30418 |

---

<sup>(1)</sup> &nbsp;&nbsp;&nbsp;&nbsp;The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM. All lines exclude depreciation, amortization and other items as noted in the above reconciliation.

A reconciliation of capital expenditures for the Company's continuing operations is shown in the following table:

---

| | | |
|:---|:---|:---|
| | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** |
| Capital expenditures: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ecoservices | $48826 | $42107 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(1)</sup> | 2770 | 854 |
| Capital expenditures per the condensed consolidated statements of cash flows | $51596 | $42961 |

---

<sup>(1)</sup> &nbsp;&nbsp;&nbsp;&nbsp;Includes corporate capital expenditures, the cash impact from changes in capital expenditures in accounts payable and capitalized interest.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**17. Stock-Based Compensation:**

The Company has an equity incentive plan under which it grants common stock awards to employees, directors and affiliates of the Company. At September 30, 2025, 7,081,030 shares of common stock were available for issuance under the plan. The Company settles these awards through the issuance of treasury shares under its equity incentive plan. The Company has granted RSAs, RSUs and PSUs as part of its equity incentive compensation program.

*RSU*

During the nine months ended September 30, 2025, the Company granted 985,551 RSUs under its equity incentive plan. Each RSU provides the recipient with the right to receive a share of common stock subject to graded vesting terms based on service, which for the awards granted during the nine months ended September 30, 2025, generally requires approximately one year of service for members of the Company's Board and approximately three years of service for employees. The value of the RSUs granted during the nine months ended September 30, 2025 was based on the average of the high and low trading prices of the Company's common stock on the NYSE on the preceding trading day, in accordance with the Company's policy for valuing such awards. Compensation expense related to the RSUs is recognized on a straight-line basis over the respective vesting period.

*PSU*

<u>2025 Grants</u>

During the nine months ended September 30, 2025, the Company granted 508,109 PSUs (at target) under its equity incentive plan. The PSUs granted during the nine months ended September 30, 2025 provide the recipients with the right to receive shares of common stock dependent on 50% of a Company-specific financial performance target and 50% on the relative increase in the total shareholder return ("TSR") goal ("the Performance measures"). The Performance measures are measured independently of each other, but achievement of both metrics is measured on the same three-year performance period from January 1, 2025 through December 31, 2027 ("Performance period"). Depending on the Company's performance relative to the Performance measures, each PSU award recipient is eligible to receive a percentage of the target number of shares granted to the recipient, ranging from zero to 200%. The PSUs, to the extent earned, will vest on the date the Compensation Committee of the Company's Board ("Compensation Committee") certifies the achievement of the Performance measures for the Performance period, which will occur subsequent to the end of the Performance period and after the Company files its annual consolidated financial statements for the year ending December 31, 2027.

Achievement of the Company-specific financial performance target is measured based on the actual three-year cumulative results across the Performance period. The TSR goal is based on the Company's actual TSR performance against companies in the S&P 1500 Specialty Chemicals Index over the Performance period. The TSR goal, which determines how much of the 50% of the PSUs granted during 2025 may be earned, is considered a market condition as opposed to a vesting condition. Because a market condition is not considered a vesting condition, it is reflected in the grant date fair value of the award and the associated compensation cost based on the fair value of the award is recognized over the Performance period, regardless of whether the Company actually achieves the market condition or the level of achievement, as long as service is provided by the recipient.

The Company used a Monte Carlo simulation to estimate the $10.80 weighted average fair value of the awards granted, subject to the TSR goal during the nine months ended September 30, 2025, with the following weighted average assumptions:

---

| | |
|:---|:---|
| Expected dividend yield | —% |
| Risk-free interest rate | 4.19% |
| Expected volatility | 40.39% |
| Expected term (in years) | 2.90 |

---

<u>2022 Grants</u>

In February 2025, the Compensation Committee certified the achievement of the performance metrics for the three-year period ended December 31, 2024, related to the PSUs granted during the year ended December 31, 2022. The PSUs granted during the year ended December 31, 2022 provide the recipients with the right to receive shares of common stock dependent on the achievement of a TSR goal and are generally subject to the provision of service through the vesting date of the award. The TSR goal was based on the Company's actual TSR percentage increase over the performance period. The awards vested during the nine months ended September 30, 2025 with no percentage of the TSR goal earned.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

*Award Activity*

The following table summarizes the activity for the Company's RSUs and PSUs for the nine months ended September 30, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Restricted Stock Units** | **Restricted Stock Units** | **Performance Stock Units** | **Performance Stock Units** | **Performance Stock Units** |
| | **Number of <br>units** | **Weighted average grant date fair value (per share)** | **Number of <br>units** | | **Weighted average grant date fair value (per share)** |
| Nonvested as of December 31, 2024 | 1977373 | $9.37 | 1353409 | (1) | $11.10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 985551 | $7.76 | 508109 |  | $9.28 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (1053456) | $9.53 |  |  | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (222182) | $8.77 | (268935) |  | $9.64 |
| Nonvested as of September 30, 2025 | 1687286 | $8.41 | 1592583 | (1) | $10.77 |

---

<sup>(1)</sup> Based on target.

During the nine months ended September 30, 2025, the Company did not grant any RSAs. Cash proceeds received by the Company from the exercise of stock options were not material for the nine months ended September 30, 2025.

***Stock-Based Compensation Expense***

For the three months ended September 30, 2025 and 2024, stock-based compensation expense for the Company included in continuing operations was $2,271 and $2,348, respectively. The associated income tax benefit based on the applicable statutory rate recognized in the condensed consolidated statements of (loss) income for the three months ended September 30, 2025 and 2024 was $620 and $576, respectively.

For the nine months ended September 30, 2025 and 2024, stock-based compensation expense for the Company included in continuing operations was $7,551 and $8,291, respectively. The associated income tax benefit based on the applicable statutory rate recognized in the condensed consolidated statements of (loss) income for the nine months ended September 30, 2025 and 2024 was $2,063 and $2,033, respectively.

As of September 30, 2025, unrecognized compensation cost of $6,439 for RSUs and $4,876 for PSUs are considered probable of vesting and the weighted-average period over which these costs are expected to be recognized at September 30, 2025 was 1.66 years for the RSUs and 1.89 years for the PSUs.

**18. Earnings per Share:**

Basic earnings per share is calculated as income available to common stockholders, divided by the weighted average number of common shares outstanding during the period. The weighted average number of common shares outstanding during the period for the computation of basic earnings per share excludes RSAs that have legally been issued but are nonvested during the period, as the sale of these shares is prohibited pending satisfaction of certain vesting conditions by the award recipients in order to earn the rights to the shares.

Diluted earnings per share is calculated as income available to common stockholders, divided by the weighted average number of common and potential common shares outstanding during the period, if dilutive. Potential common shares reflect (1) unvested RSAs and RSUs with service vesting conditions, (2) PSUs with vesting conditions considered probable of achievement and (3) options to purchase common stock, all of which have been included in the diluted earnings per share calculation using the treasury stock method.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The reconciliation from basic to diluted weighted average shares outstanding is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Weighted average shares outstanding – Basic | 113901834 | 116490634 | 115943873 | 116786759 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dilutive effect of unvested common shares and RSUs with service conditions, PSUs considered probable of vesting and assumed stock option exercises and conversions | 967439 | 696420 |  | 638495 |
| Weighted average shares outstanding – Diluted | 114869273 | 117187054 | 115943873 | 117425254 |

---

We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is income from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories.

The Company reported a net loss from continuing operations for the nine months ended September 30, 2025, and therefore excluded the dilutive effect of 521,803 shares, which consisted of unvested common shares, RSUs with service conditions, PSUs considered probable of vesting and assumed stock option exercises and conversions from the computation of weighted average diluted shares outstanding.

Basic and diluted income per share are calculated as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Numerator:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | $(79255) | $14251 | $(76866) | $23767 |
| **Denominator:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average shares outstanding – Basic | 113901834 | 116490634 | 115943873 | 116786759 |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average shares outstanding – Diluted | 114869273 | 117187054 | 115943873 | 117425254 |
| **Net (loss) income per share:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic (loss) income per share | $(0.70) | $0.12 | $(0.66) | $0.20 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted (loss) income per share | $(0.69) | $0.12 | $(0.66) | $0.20 |

---

The table below presents the details of the Company's weighted average equity-based awards outstanding during each respective period that were excluded from the calculation of diluted earnings per share:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Anti-dilutive RSUs and PSUs | 725217 | 920355 | 596900 | 419315 |
| Anti-dilutive stock options | 367100 | 367100 | 367100 | 367100 |

---

Certain stock options to purchase shares of common stock were excluded from the computation of diluted earnings per share for the respective periods because the options' exercise price was greater than the average market price of the common shares. These stock options and anti-dilutive awards are not included in the dilution calculation, as their inclusion would have the effect of increasing diluted income per share.

------

<u>[**Table of Contents**](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**19. Supplemental Cash Flow Information:**

The following table presents supplemental cash flow information for the Company, which includes activity from both continuing and discontinued operations, except for operating leases which is continuing operations only:

---

| | | |
|:---|:---|:---|
| | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** |
| Cash paid during the period for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes, net of refunds | $9957 | $20832 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest<sup>(1)</sup> | 34643 | 36982 |
| Non-cash investing activity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures acquired on account but unpaid as of the period end | 1491 | 2358 |
| Non-cash financing activity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued excise tax on share repurchases (Note 6) | 193 |  |
| Right-of-use assets obtained in exchange for new lease liabilities (non-cash): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating leases | 15094 | 8044 |

---

<sup>(1)</sup> Cash paid for interest is shown net of capitalized interest and includes the cash received or paid on the Company's interest rate cap agreements designated as cash flow hedges for the periods presented (see Note 12 to these condensed consolidated financial statements for details).

**20. Subsequent Events:**

The Company has evaluated subsequent events since the balance sheet date and determined that there are no additional items to disclose.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ITEM 2. &nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

*Unless the context requires otherwise, references in this report to "Ecovyst," "the Company," "we," "us" or "our" refer to Ecovyst Inc. and its consolidated subsidiaries.*

**Forward-looking Statements**

*This periodic report on Form 10-Q ("Form 10-Q") includes "forward-looking statements" that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should" and similar expressions are intended to identify these forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Examples of forward-looking statements include, but are not limited to, statements we make regarding statements we make regarding the announced pending sale of our Advanced Materials & Catalysts business, demand trends, economic effects on our operations and financial results and our liquidity, potential strategic acquisitions or divestitures, potential increased borrowing under our credit facilities, and our belief that our current level of operations, cash and cash equivalents, cash flow from operations and borrowings under our credit facilities and other lines of credit will provide us adequate cash to fund working capital requirements, capital expenditure projects, debt service requirements and other requirements for our business for at least the next twelve months.*

*These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.*

*Some of the key factors that could cause actual results to differ from our expectations include the following risks related to our business:*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• as a global business, we are exposed to local business risks in different countries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• are affected by general economic conditions and economic downturns;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• exchange rate fluctuations could adversely affect our financial condition, results of operations and cash flows;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our international operations require us to comply with anti-corruption laws, trade and export controls and regulations of the U.S. government and various international jurisdictions in which we do business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• alternative technology or other changes in our customers' products may reduce or eliminate the need for certain of our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our new product development and research and development efforts may not succeed and our competitors may develop more effective or successful products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our substantial level of indebtedness could adversely affect our financial condition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if we are unable to manage the current and future inflationary environment and to pass on increases in raw material prices, including natural gas, or labor costs to our customers or to retain or replace our key suppliers, our results of operations and cash flows may be negatively affected;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we face substantial competition in the industries in which we operate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we are subject to the risk of loss resulting from non-payment or non-performance by our customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we rely on a limited number of customers for a meaningful portion of our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• multi-year customer contracts are subject to potential early termination and such contracts may not be renewed at the end of their respective terms;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our quarterly results of operations are subject to fluctuations because demand for some of our products is seasonal;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our growth projects may result in significant expenditures before generating revenues, if any, which may materially and adversely affect our ability to implement our business strategy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may be liable to damages based on product liability claims brought against us or our customers for costs associated with recalls of our or our customers' products;

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we are subject to extensive environmental, health and safety regulations and face various risks associated with potential non-compliance or releases of hazardous materials;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• existing and proposed regulations to address climate change by limiting greenhouse gas emissions may cause us to incur significant additional operating and capital expenses and may impact our business and results of operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other governmental legislation and regulation, as well as adverse effects from the U.S. government shutdown;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• production and distribution of our products could be disrupted for a variety of reasons, including as a result of supply chain constraints, and such disruptions could expose us to significant losses or liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the insurance that we maintain may not fully cover all potential exposures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we could be subject to damages based on claims brought against us by our customers or lose customers as a result of the failure of our products to meet certain quality specifications;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our failure to protect our intellectual property and infringement on the intellectual property rights of third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disruption, failure or cyber security breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• significant trade developments, including tariffs, have had and may continue to have an adverse effect on us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing of, and ability to consummate, our announced sale of our Advanced Materials & Catalysts segment and the anticipated partial repayment under our 2025 Term Loan Facility;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• that we have a material weakness in our internal control over financial reporting and that we may identify additional material weaknesses in the future; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other factors set forth in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 (the "Annual Report on Form 10-K").

*The forward-looking statements included herein are made only as of the date hereof. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Form 10-Q to conform these statements to actual results or to changes in our expectations.*

**Overview** 

We are a leading provider of virgin sulfuric acid and sulfuric acid regeneration services. We believe that our Ecoservices business contributes to improving the sustainability of the environment.

We are a leading provider of sulfuric acid recycling to the North American refining industry for the production of alkylate, an essential gasoline component for lowering vapor pressure and increasing octane to meet stringent gasoline specifications and fuel efficiency standards. We are also a leading North American producer of high quality and high strength virgin sulfuric acid for industrial and mining applications. We also provide chemical waste handling and treatment services, as well as ex-situ catalyst activation services for the refining and petrochemical industry.

<u>Recent Developments</u>

On September 10, 2025, we entered into a definitive agreement to sell our Advanced Materials & Catalysts business to Technip Energies N.V. for a purchase price of $556.0 million, subject to certain adjustments including for indebtedness, cash, working capital and transaction expenses. The transaction is expected to be completed in the first quarter of 2026, subject to regulatory approvals and customary closing conditions. The results of operations, financial condition, and cash flows for the Advanced Materials & Catalysts are presented herein as discontinued operations. Except where noted, any tables, percentages or metrics included within this filing exclude the results of our Advanced Materials & Catalysts business. Refer to Note 3 to our condensed consolidated financial statements for additional information.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

*Stock Repurchase Program*

On April 27, 2022, our Board of Directors (the "Board") approved a stock repurchase program that authorized the Company to purchase up to $450.0 million of the Company's common stock over the four-year period from the date of approval (the "Stock Repurchase Program"). On October 30, 2025, the Board amended the Stock Repurchase Program to remove the limitation that all repurchases must be made within the four-year period from the date of original approval. For the nine months ended September 30, 2025, the Company repurchased 3,536,364 shares on the open market at an average price of $7.74 per share, for a total of $27.4 million excluding brokerage commissions and accrued excise tax. As of September 30, 2025, $202.2 million was available for share repurchases under the program.

For the nine months ended September 30, 2024, the Company repurchased 552,081 shares on the open market at an average price of $9.05 per share, for a total of $5.0 million excluding brokerage commissions and accrued excise tax.

For possible future repurchases, the actual timing, number, and nature of shares repurchased will depend on a variety of factors, including stock price, trading volume, and general business and market conditions and may be conducted through negotiated transactions, open market repurchases or other means, including through Rule 10b-18 and 10b5-1 trading plans or accelerated share repurchases.

**Key Performance Indicators**

***Adjusted EBITDA, Adjusted Net Income and Net Debt***

Adjusted EBITDA, Adjusted Net Income and Net Debt are financial measures that are not prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and that we use to evaluate our operating performance, for business planning purposes and to measure our performance relative to that of our competitors. Adjusted EBITDA, Adjusted Net Income, and Net Debt are presented as key performance indicators as we believe these financial measures will enhance a prospective investor's understanding of our results of operations and financial condition. EBITDA consists of net income (loss) from continuing operations before interest, taxes, depreciation and amortization. Adjusted EBITDA consists of EBITDA adjusted for (i) non-operating income or expense, and (ii) the impact of certain non-cash, nonrecurring or other items included in net income and EBITDA that we do not consider indicative of our ongoing operating performance. Adjusted Net Income consists of net income (loss) from continuing operations adjusted for (i) non-operating income or expense and (ii) the impact of certain non-cash, nonrecurring or other items included in net income that we do not consider indicative of our ongoing operating performance. Net Debt consists of total debt less cash and cash equivalents. We believe that these non-GAAP financial measures provide investors with useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

You should not consider Adjusted EBITDA, Adjusted Net Income, or Net Debt in isolation or as alternatives to the presentation of our financial results in accordance with GAAP. The presentation of Adjusted EBITDA, Adjusted Net Income and Net Debt financial measures may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures. In evaluating Adjusted EBITDA and Adjusted Net Income, you should be aware that we are likely to incur expenses similar to those eliminated in this presentation in the future and that certain of these items could be considered recurring in nature. Our presentation of Adjusted EBITDA and Adjusted Net Income should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. Reconciliations of Adjusted EBITDA, Adjusted Net Income to GAAP net income and Net Debt to GAAP total debt are included in this "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" for each of the respective periods.

**Key Factors and Trends Affecting Operating Results and Financial Condition**

***Sales***

Sales are made on both a purchase order basis and pursuant to long-term contracts. We continued to benefit from positive demand trends for our products and services in the majority of end uses we serve. Strong domestic and export demand for refined products continued to support high refinery utilization rates, while more stringent gasoline standards and growing demand for premium gasoline to power higher-compression and turbo-charged engines continued to drive demand for alkylate and for our regeneration services. In addition, demand for virgin sulfuric acid across a wide range of industrial applications remained favorable.

***Cost of Goods Sold***

Cost of goods sold consists of variable product costs, fixed manufacturing expenses, depreciation expense and freight expenses. Variable product costs include all raw materials and energy costs that are directly related to the manufacturing process. Fixed manufacturing expenses include all plant employment costs, manufacturing overhead and periodic maintenance costs.

The primary raw materials for our Ecoservices segment include spent sulfuric acid, sulfur, acids, bases (including sodium hydroxide, or "caustic soda") and certain metals. Spent sulfuric acid for our Ecoservices segment is supplied by customers as part of their contracts.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

Most of our contracts feature take-or-pay volume protection and/or quarterly price adjustments for commodity inputs, labor, the Chemical Engineering Index (U.S. chemical plant construction cost index) and natural gas. About 90% of our sales for the year ended December 31, 2024 were under contracts featuring quarterly price adjustments. The price adjustments generally reflect actual costs for producing acid and tend to protect us from volatility in labor, fixed costs and raw material pricing. The take-or-pay volume protection allows us to cover fixed costs through intermittent, temporary production issues at customer refineries.

While natural gas is not a direct feedstock for any product, natural gas powered machinery and equipment are used to heat raw materials and create the chemical reactions necessary to produce end-products. We maintain multiple suppliers wherever possible and structure our customer contracts when possible to allow for the pass-through of raw material, labor and natural gas costs.

***Seasonality***

Our regeneration services product group typically experiences seasonal fluctuations as a result of higher demand for gasoline products in the summer months and lower demand in the winter months. These demand fluctuations generally result in higher sales and working capital requirements in the second and third quarters.

**Results of Operations** 

***Three Months Ended September 30, 2025 Compared to the Three Months Ended September 30, 2024***

***Highlights***

The following is a summary of our financial performance for the three months ended September 30, 2025 compared to the three months ended September 30, 2024.

*Sales*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Sales increased $51.0 million to $204.9 million. The increase in sales primarily reflects higher average selling prices from the pass-through effect of higher sulfur costs, favorable contractual pricing for regeneration services, increased volume of virgin sulfuric acid, as well as sales associated with the acquired Waggaman, Louisiana location, partially offset by lower regeneration services volume.

*Gross Profit*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit increased $7.0 million to $52.1 million. The increase in gross profit was primarily due to higher average selling pricing and higher sales volume, partially offset by higher manufacturing costs.

*Operating Income*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating income increased by $0.8 million to $28.3 million. The increase in operating income reflects higher gross profit offset by higher other operating expense, net.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

The following is our unaudited condensed consolidated statements of (loss) income and a summary of financial results for the three months ended September 30, 2025 and 2024:

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Change** |
| | **2025** | **2024** | $**%** |
| | **(in millions, except percentages)** | **(in millions, except percentages)** | **(in millions, except percentages)** |
| Sales | $204.9 | $153.9 | 33.1% |
| Cost of goods sold | 152.8 | 108.8 | 40.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 52.1 | 45.1 | 15.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit margin | *25.4 %* | *29.3 %* |  |
| Selling, general and administrative expenses | 15.7 | 15.2 | 3.3% |
| Other operating expense, net | 8.1 | 2.4 | 237.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income | 28.3 | 27.5 | 2.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income margin | *13.8 %* | *17.9 %* |  |
| Interest expense, net | 8.4 | 7.9 | 6.3% |
| Other (income) expense, net | (0.7) | 0.2 | (450.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income before income taxes | 20.6 | 19.4 | 6.2% |
| Provision for income taxes | 20.2 | 4.6 | 339.1% |
| Effective tax rate | *98.2 %* | *23.7 %* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income from continuing operations | 0.4 | 14.8 | (97.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss from discontinued operations, net of tax | (79.7) | (0.5) | 15840.0% |
| Net (loss) income | $(79.3) | $14.3 | (654.5)% |

---

***Sales***

Sales for the three months ended September 30, 2025 were $204.9 million, an increase of $51.0 million, or 33.1%, compared to sales of $153.9 million for the three months ended September 30, 2024. The increase in sales was due to higher average selling prices of $34.3 million and higher overall sales volume of $16.7 million.

The increase in average selling prices primarily reflect the pass-through effect of higher sulfur costs and favorable contractual pricing for regeneration services. The impact associated with the pass-through of high sulfur costs was approximately $25 million for the three months ended September 30, 2025. The increase in sales volume was primarily related to the contribution of sales volume from the Waggaman location and higher virgin sulfuric acid sales, partially offset by lower regeneration services due to unplanned and extended customer downtime.

***Gross Profit***

Gross profit for the three months ended September 30, 2025 was $52.1 million, an increase of $7.0 million, or 15.5%, compared to $45.1 million for the three months ended September 30, 2024. The increase in gross profit was primarily due to higher average selling prices of $9.3 million, exclusive of the approximately $25 million pass-through of the higher sulfur costs, driven by contractual improvements and higher sales volume of $5.8 million, partially offset by higher manufacturing costs of $8.2 million, exclusive of the sulfur costs. The cost of sulfur is generally passed-through to customers at the same rate as incurred resulting in no net impact to gross profit.

Higher manufacturing costs were driven by additional fixed costs from the Waggaman location, general inflation and transportation.

***Selling, General and Administrative Expenses***

Selling, general and administrative expenses were $15.7 million for the three months ended September 30, 2025, an increase of $0.5 million, as compared to $15.2 million for three months ended September 30, 2024.

***Other Operating Expense, Net***

Other operating expense, net for the three months ended September 30, 2025 was $8.1 million, an increase of $5.7 million, compared to $2.4 million for the three months ended September 30, 2024. The increase in other operating expense, net was primarily due to an increase in loss on disposal of assets of $3.4 million, transaction and integration costs associated with the Waggaman location of $1.3 million, and other costs of $1.0 million, primarily related to restructuring and tax charges.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

***Interest Expense, Net***

Interest expense, net for the three months ended September 30, 2025 was $8.4 million, an increase of $0.5 million, as compared to $7.9 million for the three months ended September 30, 2024. The increase in interest expense, net was due to lower benefit from our interest rate caps offset by lower interest expense driven by the year over year decrease in variable rates in part due to the reduction in our spread associated with the 2025 Term Loan refinancing transactions and lower outstanding debt during the three months ended September 30, 2025, as compared to the three months ended September 30, 2024.

***Other (Income) Expense, Net***

Other income, net for the three months ended September 30, 2025 was $0.7 million, a change of $0.9 million, as compared to $0.2 million of other expense for the three months ended September 30, 2024.

***Provision For Income Taxes***

The provision for income taxes for the three months ended September 30, 2025 was $20.2 million, compared to $4.6 million for the three months ended September 30, 2024. The effective income tax rate for the three months ended September 30, 2025 was 98.2%, compared to 23.7% for the three months ended September 30, 2024. The Company's quarter over quarter effective income tax rate has fluctuated primarily due to an increased discrete tax impact relative to pre-tax book income. The discrete tax items relate to a stock compensation shortfall, intraperiod allocation revaluation of deferred tax assets and liabilities including valuation allowances as a result of the Advanced Materials & Catalysts divestiture, tax expense associated with the recording of accrued penalties and interest on historical uncertain tax positions and a tax benefit related to state tax refunds associated with prior tax years.

The total tax expense for the three months ended September 30, 2025 includes a $15.6 million discrete tax expense connected to intraperiod allocation associated with the revaluation of deferred tax assets and liabilities, a valuation allowance against the Company's Kansas Investment Tax Credits, and an increase in valuation allowance against a portion of the Company's state net operating losses. In accordance with intraperiod allocation rules, this discrete tax expense is reflected in the tax provision for continuing operations.

The difference between the U.S. federal statutory income tax rate and the Company's effective income tax rate for the three months ended September 30, 2025 was mainly due to state and local taxes, shortfall tax expense related to stock compensation, tax benefit related to state tax refunds associated with prior tax years, discrete tax expense related to intraperiod allocation associated with the revaluation of deferred tax assets and liabilities, a valuation allowance against the Company's Kansas Investment Tax Credits, and a valuation allowance against a portion of the Company's state net operating losses.

***Net Income From Continuing Operations***

For the foregoing reasons, net income from continuing operations was $0.4 million for the three months ended September 30, 2025, compared to $14.8 million for the three months ended September 30, 2024.

***Adjusted EBITDA***

Summarized Adjusted EBITDA information is shown below in the following table:

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** | **Change** |
| | **2025** | **2024** | $**%** |
| | **(in millions, except percentages)** | **(in millions, except percentages)** | **(in millions, except percentages)** |
| Adjusted EBITDA:<sup>(1)</sup> |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Ecoservices | $63.6 | $55.1 | 15.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Unallocated corporate expenses | (6.1) | (6.4) | 4.7% |
| Total | $57.5 | $48.7 | 18.1% |

---

<sup>(1)</sup> We define Adjusted EBITDA as EBITDA adjusted for certain items as noted in the reconciliation below. Our management evaluates the performance of our segments and allocates resources based primarily on Adjusted EBITDA. Adjusted EBITDA does not represent cash flow for periods presented and should not be considered as an alternative to net income from continuing operations as an indicator of our operating performance or as an alternative to cash flows as a source of liquidity. Adjusted EBITDA may not be comparable with EBITDA or Adjusted EBITDA as defined by other companies.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

*Ecoservices:* Adjusted EBITDA for the three months ended September 30, 2025 was $63.6 million, an increase of $8.5 million, or 15.4%, compared to $55.1 million for the three months ended September 30, 2024. The increase in Adjusted EBITDA was a result of favorable contractual pricing for regeneration services and higher sales volume of virgin sulfuric acid, partially offset by lower regeneration services volume, due to unplanned and extended customer down time, and higher manufacturing costs driven by general inflation and transportation.

A reconciliation of net income from continuing operations to Adjusted EBITDA is as follows:

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>September 30,** | **Three months ended<br>September 30,** |
| | **2025** | **2024** |
|  | **(in millions)** | **(in millions)** |
| **Reconciliation of net income from continuing operations to Adjusted EBITDA** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income from continuing operations | $0.4 | $14.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 20.2 | 4.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 8.4 | 7.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 20.7 | 18.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EBITDA | 49.7 | 45.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset disposals<sup>(a)</sup> | 3.6 | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction and other related costs<sup>(b)</sup> | 0.6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 2.3 | 2.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring, integration and business optimization expenses<sup>(c)</sup> | 1.8 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(d)</sup> | (0.5) | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA | $57.5 | $48.7 |

---

<sup>(a)</sup>When asset disposals occur, we remove the impact of net gain/loss of the disposed asset because such impact primarily reflects the non-cash write-off of long-lived assets no longer in use.

<sup>(b)</sup>Relates to certain transaction costs, including debt financing, due diligence and other costs related to transactions that are completed, pending or abandoned, that we believe are not representative of our ongoing business operations.

<sup>(c)</sup>Includes the impact of restructuring, integration and business optimization expenses, which are incremental costs that are not representative of our ongoing business operations.

<sup>(d)</sup>Other consists of adjustments for items that are not core to our ongoing business operations. These adjustments include environmental remediation and other legal costs, expenses for capital and franchise taxes, and defined benefit pension and postretirement plan (benefits) costs, for which our obligations are under plans that are frozen. Included in this line-item are rounding discrepancies that may arise from rounding from dollars (in thousands) to dollars (in millions).

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

***Adjusted Net Income***

Summarized Adjusted Net Income information is shown below in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** |
| | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
| | **Pre-tax amount** | **Tax expense (benefit)** | **After-tax amount** | **Pre-tax amount** | **Tax expense (benefit)** | **After-tax amount** |
| | **(in millions)** | **(in millions)** | **(in millions)** | **(in millions)** | **(in millions)** | **(in millions)** |
| **Reconciliation of net income from continuing operations to Adjusted Net Income**<sup>(1)(2)</sup> |  |  |  |  |  |  |
| Net income from continuing operations | $20.6 | $20.2 | $0.4 | $19.4 | $4.6 | $14.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset disposals<sup>(a)</sup> | 3.6 | 0.9 | 2.7 | 0.2 | 0.1 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction and other related costs<sup>(b)</sup> | 0.6 | 0.2 | 0.4 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 2.3 | 0.6 | 1.7 | 2.3 | 0.6 | 1.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring, integration and business optimization expenses<sup>(c)</sup> | 1.8 | 0.5 | 1.3 | 0.1 |  | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(d)</sup> | (0.3) | (0.1) | (0.2) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted Net Income, including intraperiod allocation | 28.6 | 22.3 | 6.3 | 22.0 | 5.3 | 16.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intraperiod allocation for restating discontinued operations<sup>(3)</sup> |  | (15.6) | 15.6 |  |  |  |
| Adjusted Net Income | $28.6 | $6.7 | $21.9 | $22.0 | $5.3 | $16.7 |

---

<sup>(1)</sup> We define Adjusted Net Income as net income from continuing operations adjusted for non-operating income or expense and the impact of certain non-cash or other items that are included in net income from continuing operations that we do not consider indicative of our ongoing operating performance. Adjusted Net Income is presented as a key performance indicator as we believe it will enhance a prospective investor's understanding of our results of operations and financial condition. Adjusted Net Income may not be comparable with net income from continuing operations or Adjusted Net Income as defined by other companies.

<sup>(2)</sup> Refer to the Adjusted EBITDA notes above for more information with respect to each adjustment.

<sup>(3)</sup> Due to reporting the Advanced Materials & Catalysts business as held for sale in discontinued operations, the estimated tax rate used to value deferred tax assets ("DTAs") and deferred tax liabilities ("DTLs") needs to be adjusted to remove the Advanced Materials & Catalysts rate. Additionally, the Company reassessed the realizability of its state deferred tax assets, including Kansas Investment Tax Credits and state Net Operating Losses. Due to changes in the Company's state apportionment profile resulting from the Advanced Materials & Catalysts, it was determined that a portion of these deferred tax assets are no longer expected to be realized. Accordingly, the Company recorded a valuation allowance during the quarter to reflect the reduced expected benefit of these state tax attributes. Given these are a direct result of the sale of discontinued operations and the need to adjust the estimated tax rate and valuation allowances arose because of discontinued operations, the impacts are reflected in continuing operations. Due to these revaluations being solely as a result of the Advanced Materials & Catalysts divestiture and a non-cash item, it is treated as an addback.

The adjustments to net income from continuing operations are shown net of applicable tax rates as determined by the calculation of our quarterly tax provision under interim financial reporting for the three months ended September 30, 2025 and September 30, 2024, except for equity-based compensation. The tax effect on equity-based compensation is derived by removing the tax effect of any equity-based compensation expense disallowed as a result of its inclusion within Section 162(m) of the Internal Revenue Code of 1986 (as amended) and adjusting for the tax effect of the equity-based stock compensation net windfall or shortfall which is recorded as a discrete item.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**Results of Operations**

***Nine Months Ended September 30, 2025 Compared to the Nine Months Ended September 30, 2024***

***Highlights***

The following is a summary of our financial performance for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024.

*Sales*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Sales increased $74.7 million to $524.1 million. The increase in sales primarily reflects higher average selling prices from the pass-through effect of higher sulfur costs, favorable contractual pricing for regeneration services and sales associated with the acquired Waggaman, Louisiana location, partially offset by lower regeneration services volume.

*Gross Profit*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit decreased $9.0 million to $111.4 million. The decrease in gross profit was primarily due to lower regeneration services volume and higher manufacturing costs, partially offset by higher average selling prices.

*Operating Income*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating income decreased by $19.6 million to $43.1 million. The decrease in operating income was due to a decrease in gross profit and higher other operating expense, net, partially offset by lower selling, general and administrative expenses.

The following is our unaudited condensed consolidated statements of (loss) income and a summary of financial results for the nine months ended September 30, 2025 and 2024:

---

| | | | |
|:---|:---|:---|:---|
| | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Change** |
| | **2025** | **2024** | $**%** |
| | **(in millions, except percentages)** | **(in millions, except percentages)** | **(in millions, except percentages)** |
| Sales | $524.1 | $449.4 | 16.6% |
| Cost of goods sold | 412.7 | 329.0 | 25.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 111.4 | 120.4 | (7.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit margin | *21.2 %* | *26.8 %* |  |
| Selling, general and administrative expenses | 49.8 | 49.8 | —% |
| Other operating expense, net | 18.5 | 7.9 | 134.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income | 43.1 | 62.7 | (31.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income margin | *8.2 %* | *13.9 %* |  |
| Interest expense, net | 24.8 | 27.1 | (8.5)% |
| Debt modification and extinguishment costs | 1.0 | 4.6 | (78.3)% |
| Other (income) expense, net | (0.3) | 0.6 | (150.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income before income taxes | 17.6 | 30.4 | (42.1)% |
| Provision for income taxes | 20.0 | 8.0 | 150.0% |
| Effective tax rate | *113.4 %* | *26.4 %* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income from continuing operations | (2.4) | 22.4 | (110.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income from discontinued operations, net of tax | (74.5) | 1.4 | (5421.4)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | $(76.9) | $23.8 | (423.1)% |

---

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

***Sales***

Sales for the nine months ended September 30, 2025 were $524.1 million, an increase of $74.7 million, or 16.6%, compared to sales of $449.4 million for the nine months ended September 30, 2024. The increase in sales reflects higher average selling prices of $65.6 million, including the pass-through effect of higher sulfur costs of approximately $49 million, and higher sales volume of $9.1 million.

Average selling prices were higher primarily due to the pass-through effect of higher sulfur costs, favorable contract pricing for regeneration services. Sales volume increase was a result of the contribution of sales volume from the Waggaman location, partially offset by lower regeneration services driven by unplanned and extended customer down-time and maintenance turnaround activity at our facilities.

***Gross Profit***

Gross profit for the nine months ended September 30, 2025 was $111.4 million, a decrease of $9.0 million, or 7.5%, compared to $120.4 million for the nine months ended September 30, 2024. The decrease in gross profit was primarily driven by higher manufacturing costs of $23.9 million, exclusive of the approximately $49 million of higher sulfur costs, and lower sales volume of $1.8 million, partially offset by higher average selling prices of $16.6 million, exclusive of the pass-through of sulfur costs. The cost of sulfur is generally passed-through to customers at the same rate as incurred resulting in no net impact to gross profit.

Higher manufacturing costs were driven by additional fixed costs from the Waggaman location, general inflation, maintenance and transportation.

***Selling, General and Administrative Expenses***

Selling, general and administrative expenses for the nine months ended September 30, 2025 and 2024 were $49.8 million.

***Other Operating Expense, Net***

Other operating expense, net for the nine months ended September 30, 2025 was $18.5 million, an increase of $10.6 million, compared to $7.9 million for the nine months ended September 30, 2024. The increase in other operating expense, net was mainly driven by an increase in loss on disposal of assets of $3.2 million, transaction and integration costs associated with the Waggaman location of $4.1 million, and other costs of $3.3 million primarily related to restructuring and tax charges.

***Interest Expense, Net***

Interest expense, net for the nine months ended September 30, 2025 was $24.8 million, a decrease of $2.3 million, as compared to $27.1 million for the nine months ended September 30, 2024. The decrease in interest expense, net was primarily due to the year over year decrease in variable rates in part due to the reduction in our spread associated with the 2025 Term Loan refinancing transactions and lower outstanding debt during the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024, partially offset by lower benefit from our interest rate caps.

***Debt Modification and Extinguishment Costs***

Debt modification and extinguishment costs for the nine months ended September 30, 2025 were $1.0 million, a decrease of $3.6 million, as compared to $4.6 million for the nine months ended September 30, 2024.

On January 30, 2025, we amended our existing senior secured term loan facility to reduce the applicable interest rates. The Company evaluated the terms of the amendment in accordance with *ASC 470-50 Debt - Modification and Extinguishment* and determined that the amendment was a modification of debt. As a result, we recorded $1.0 million of third-party financing fees within debt modification and extinguishment costs in the condensed consolidated statements of (loss) income during the nine months ended September 30, 2025.

On June 12, 2024, we amended our existing senior secured term loan facility to reduce the applicable interest rates and extend the maturity of the facility to June 2031. The Company evaluated the terms of the amendment in accordance with *ASC 470-50 Debt - Modification and Extinguishment* and determined that the amendment was primarily a modification of debt. As a result, we recorded $4.5 million of third-party financing fees within debt modification and extinguishment costs in the condensed consolidated statements of (loss) income during the nine months ended September 30, 2024. In addition, previously unamortized deferred financing costs and original issue discount of $0.1 million associated with the existing senior secured term loan facility were written off as debt extinguishment costs for the nine months ended September 30, 2024.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

***Other (Income) Expense, Net***

Other income, net for the nine months ended September 30, 2025 was $0.3 million, a change of $0.9 million, as compared to $0.6 million of other expense for the nine months ended September 30, 2024.

***Provision For Income Taxes***

The provision for income taxes for the nine months ended September 30, 2025 was $20.0 million, compared to $8.0 million for the nine months ended September 30, 2024. The effective income tax rate for the nine months ended September 30, 2025 was 113.4%, compared to 26.4% for the nine months ended September 30, 2024.

The Company's effective income tax rate for the nine months ended September 30, 2025 and 2024, respectively, fluctuated primarily due to an increased discrete tax impact relative to pre-tax book income. The discrete tax items relate to a stock compensation shortfall, intraperiod allocation revaluation of deferred tax assets and liabilities including valuation allowances as a result of the Advanced Materials & Catalysts divestiture, tax expense associated with the recording of accrued penalties and interest on historical uncertain tax positions, and a tax benefit related to state tax refunds associated with prior tax years.

The total tax expense for the nine months ended September 30, 2025 includes a $15.6 million discrete tax expense connected to intraperiod allocation associated with the revaluation of deferred tax assets and liabilities, a valuation allowance against the Company's Kansas Investment Tax Credits, and an increase in valuation allowance against a portion of the Company's state net operating losses. In accordance with intraperiod allocation rules, this discrete tax expense is reflected in the tax provision for continuing operations.

The difference between the U.S. federal statutory income tax rate and the Company's effective income tax rate for the nine months ended September 30, 2025 was mainly due to state and local taxes, shortfall tax expense related to stock compensation, tax benefit related to state tax refunds associated with prior tax years, discrete tax expense related to intraperiod allocation associated with the revaluation of deferred tax assets and liabilities, a valuation allowance against the Company's Kansas Investment Tax Credits, and a valuation allowance against a portion of the Company's state net operating losses.

***Net (Loss) Income From Continuing Operations***

For the foregoing reasons, net loss from continuing operations was $2.4 million for the nine months ended September 30, 2025, compared to net income from continuing operations of $22.4 million for the nine months ended September 30, 2024.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

***Adjusted EBITDA***

Summarized Adjusted EBITDA information is shown below in the following table:

---

| | | | |
|:---|:---|:---|:---|
| | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** | **Change** |
| | **2025** | **2024** | $**%** |
| | **(in millions, except percentages)** | **(in millions, except percentages)** | **(in millions, except percentages)** |
| Adjusted EBITDA<sup>(1)</sup> |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Ecoservices | $141.9 | $146.3 | (3.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Unallocated corporate expenses | (21.2) | (21.4) | 0.9% |
| Total | $120.7 | $124.9 | (3.4)% |

---

<sup>(1)</sup> We define Adjusted EBITDA as EBITDA adjusted for certain items as noted in the reconciliation below. Our management evaluates the performance of our segments and allocates resources based primarily on Adjusted EBITDA. Adjusted EBITDA does not represent cash flow for periods presented and should not be considered as an alternative to net (loss) income from continuing operations as an indicator of our operating performance or as an alternative to cash flows as a source of liquidity. Adjusted EBITDA may not be comparable with EBITDA or Adjusted EBITDA as defined by other companies.

*Ecoservices:* Adjusted EBITDA for the nine months ended September 30, 2025 was $141.9 million, a decrease of $4.4 million, or 3.0%, compared to $146.3 million for the nine months ended September 30, 2024. The decrease in Adjusted EBITDA was driven by lower volumes in regeneration services driven by unplanned and extended customer down-time and maintenance turnaround activity at our facilities and higher manufacturing costs driven by general inflation, maintenance and transportation, partially offset by favorable contractual pricing in regeneration services.

A reconciliation of net (loss) income from continuing operations to Adjusted EBITDA is as follows:

---

| | | |
|:---|:---|:---|
| | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** |
| | **(in millions)** | **(in millions)** |
| **Reconciliation of net (loss) income from continuing operations to Adjusted EBITDA** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income from continuing operations | $(2.4) | $22.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 20.0 | 8.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 24.8 | 27.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 58.0 | 52.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EBITDA | 100.4 | 110.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt modification and extinguishment costs | 1.0 | 4.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset disposals<sup>(a)</sup> | 4.0 | 0.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction and other related costs<sup>(b)</sup> | 2.8 | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 7.6 | 8.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring, integration and business optimization expenses<sup>(c)</sup> | 2.9 | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(d)</sup> | 2.0 | 0.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA | $120.7 | $124.9 |

---

<sup>(a)</sup>When asset disposals occur, we remove the impact of net gain/loss of the disposed asset because such impact primarily reflects the non-cash write-off of long-lived assets no longer in use.

<sup>(b)</sup>Relates to certain transaction costs, including debt financing, due diligence and other costs related to transactions that are completed, pending or abandoned, that we believe are not representative of our ongoing business operations.

<sup>(c)</sup>Includes the impact of restructuring, integration and business optimization expenses, which are incremental costs that are not representative of our ongoing business operations.

<sup>(d)</sup>Other consists of adjustments for items that are not core to our ongoing business operations. These adjustments include environmental remediation and other legal costs, expenses for capital and franchise taxes, and defined benefit pension and postretirement plan (benefits) costs, for which our obligations are under plans that are frozen. Included in this line-item are rounding discrepancies that may arise from rounding from dollars (in thousands) to dollars (in millions).

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

***Adjusted Net Income***

Summarized Adjusted Net Income information is shown below in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
| | **Pre-tax amount** | **Tax expense (benefit)** | **After-tax amount** | **Pre-tax amount** | **Tax expense (benefit)** | **After-tax amount** |
| | **(in millions)** | **(in millions)** | **(in millions)** | **(in millions)** | **(in millions)** | **(in millions)** |
| **Reconciliation of net (loss) income from continuing operations to Adjusted Net Income**<sup>(1)(2)</sup> |  |  |  |  |  |  |
| Net (loss) income from continuing operations | $17.6 | $20 | $(2.4) | $30.4 | $8 | $22.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt modification and extinguishment costs | 1.0 | 0.2 | 0.8 | 4.6 | 1.1 | 3.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset disposals<sup>(a)</sup> | 4.0 | 1.0 | 3.0 | 0.8 | 0.2 | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction and other related costs<sup>(b)</sup> | 2.8 | 0.7 | 2.1 | 0.2 | 0.1 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 7.6 | 0.9 | 6.7 | 8.3 | 1.6 | 6.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring, integration and business optimization expenses<sup>(c)</sup> | 2.9 | 0.8 | 2.1 | 0.2 | 0.1 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(d)</sup> | 1.9 | 0.5 | 1.4 | 0.3 | 0.2 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted Net Income, including intraperiod allocation | 37.8 | 24.1 | 13.7 | 44.8 | 11.3 | 33.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intraperiod allocation for restating discontinued operations<sup>(3)</sup> |  | (15.6) | 15.6 |  |  |  |
| Adjusted Net Income | $37.8 | $8.5 | $29.3 | $44.8 | $11.3 | $33.5 |

---

<sup>(1)</sup> We define Adjusted Net Income as net (loss) income from continuing operations adjusted for non-operating income or expense and the impact of certain non-cash or other items that are included in net (loss) income from continuing operations that we do not consider indicative of our ongoing operating performance. Adjusted Net Income is presented as a key performance indicator as we believe it will enhance a prospective investor's understanding of our results of operations and financial condition. Adjusted Net Income may not be comparable with net (loss) income from continuing operations or Adjusted Net Income as defined by other companies.

<sup>(2)</sup> Refer to the Adjusted EBITDA notes above for more information with respect to each adjustment.

<sup>(3)</sup> Due to reporting the Advanced Materials & Catalysts business as held for sale in discontinued operations, the estimated tax rate used to value DTAs and DTLs needs to be adjusted to remove the Advanced Materials & Catalysts rate. Additionally, the Company reassessed the realizability of its state deferred tax assets, including Kansas Investment Tax Credits and state Net Operating Losses. Due to changes in the Company's state apportionment profile resulting from the Advanced Materials & Catalysts, it was determined that a portion of these deferred tax assets are no longer expected to be realized. Accordingly, the Company recorded a valuation allowance during the quarter to reflect the reduced expected benefit of these state tax attributes. Given these are a direct result of the sale of discontinued operations and the need to adjust the estimated tax rate and valuation allowances arose because of discontinued operations, the impacts are reflected in continuing operations. Due to these revaluations being solely as a result of the Advanced Materials & Catalysts divestiture and a non-cash item, it is treated as an addback.

The adjustments to net (loss) income from continuing operations are shown net of applicable tax rates of 25.6% and 25.1% for the nine months ended September 30, 2025 and 2024, respectively, except for equity-based compensation. The tax effect on equity-based compensation is derived by removing the tax effect of any equity-based compensation expense disallowed as a result of its inclusion within Section 162(m) of the Internal Revenue Code of 1986 (as amended) and adjusting for the tax effect of the equity-based stock compensation net windfall or shortfall which is recorded as a discrete item

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**Financial Condition, Liquidity and Capital Resources**

Our primary sources of liquidity consist of cash flows from operations, existing cash balances as well as funds available under our asset based lending revolving credit facility ("ABL Facility"). We expect that ongoing requirements for debt service and capital expenditures will be funded from these sources of funds. Our primary liquidity requirements include funding working capital requirements (primarily inventory and accounts receivable, net of accounts payable and other accrued liabilities), debt service requirements and capital expenditures. Our capital expenditures include both maintenance of business, which include spending on maintenance and health, safety and environmental initiatives as well as growth, which includes spending to drive organic sales growth and cost savings initiatives.

We believe that our existing cash and cash equivalents and cash flows from operations, combined with availability under our ABL Facility, will be sufficient to meet our presently anticipated future cash needs for at least the next twelve months. We may also pursue strategic acquisition or divestiture opportunities, which may impact our future cash requirements. We may, from time to time, increase borrowings under our ABL Facility to meet our future cash needs. As of September 30, 2025, we had cash and cash equivalents of $99.1 million, including $82.0 million cash and cash equivalents from continuing operations and $17.1 million of cash and cash equivalents from discontinued operations, and availability of $85.6 million under our ABL Facility, after giving effect to $3.3 million of outstanding letters of credit, for a total available liquidity of $184.7 million. We did not have any revolving credit facility borrowings as of September 30, 2025. As of September 30, 2025, we were in compliance with all covenants under our debt agreements.

Prior to April 10, 2025, our ABL Facility had one financial covenant with two ratios to maintain. The first ratio compared the total ABL availability against a threshold: the greater of 10% of the line cap (which was defined as the lesser of our revolving loan commitments and the value of our assets) or $10.0 million. The greater of this threshold could not be greater than the total availability of the ABL Facility. The second ratio compared the ABL Facility availability of the U.S. revolving credit facility against a $7.5 million threshold. As of September 30, 2025, we were in compliance with the financial covenant under the ABL Facility. On April 10, 2025, we amended the ABL Facility to, among other things, reallocate all European revolving loan commitments thereunder as U.S. revolving loan commitments. As a result of the amendment, on and after April 10, 2025, the U.S. revolving credit facility comprises all availability of the ABL Facility, and we are only required to comply with the first ratio described above.

The 2025 Term Loan Facility and the ABL Facility contain various restrictive covenants. Each limits the ability of the Company and its restricted subsidiaries to incur certain indebtedness or liens, merge, consolidate or liquidate, dispose of certain property, make investments or declare or pay dividends, make optional payments, modify certain debt instruments, enter into certain transactions with affiliates, enter into certain sales and leasebacks and certain other non-financial restrictive covenants. During such time, the Company is required to maintain a fixed-charge coverage ratio of at least 1.0 to 1.0. The Company was in compliance with all debt covenants under the 2025 Term Loan Facility and the ABL Facility as of September 30, 2025.

Upon the close of the sale of the Advanced Materials & Catalysts business and finalization of net cash proceeds, the Company will be required to provide partial repayment under its 2025 Term Loan Facility.

We have no cash and cash equivalents held in foreign jurisdictions on a continuing operations basis.

Our liquidity requirements include interest payments related to our debt structure. As reported, our cash interest paid for the nine months ended September 30, 2025 and 2024 was approximately $34.6 million and $37.0 million, respectively. Before any impact of hedges, a one percent change in assumed interest rates for our variable interest credit facilities would have an annual impact of approximately $8.6 million on interest expense.

We hedge the interest rate fluctuations on debt obligations through interest rate cap agreements. For more information about our interest rate cap agreements, refer to Note 12 — Financial Instruments of our condensed consolidated financials statements included in Part 1, Item 1 — Financial Statements (Unaudited).

***Off-Balance Sheet Arrangements***

The Company's off-balance sheet arrangements include $3.3 million of outstanding letters of credit on our ABL Facility as of September 30, 2025.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

***Cash Flow***

---

| | | |
|:---|:---|:---|
| | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** |
| | **(in millions)** | **(in millions)** |
| *Continuing Operations* |  |  |
| Net cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating activities | $77.5 | $66.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing activities | (92.9) | (43.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing activities | (35.1) | (12.7) |
| *Discontinued Operations* |  |  |
| Net cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating activities | 21.0 | 40.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing activities | (15.5) | (13.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing activities | (2.4) | (2.4) |
| Effect of exchange rate changes on cash and cash equivalents | 0.5 |  |
| Net change in cash and cash equivalents | (46.9) | 35.1 |
| Cash and cash equivalents at beginning of period | 146.0 | 88.4 |
| Cash and cash equivalents at end of period | 99.1 | 123.5 |
| Less: cash, cash equivalents, and restricted cash of discontinued operations | (17.1) | (23.3) |
| Cash, cash equivalents and restricted cash at end of period of continuing operations | $82.0 | $100.2 |

---

The following discussions related to our cash flows are presented on a continuing operations basis, which excludes the cash flows from our Advanced Materials & Catalysts businesses accounted for as discontinued operations.

Net cash provided by operating activities was $77.5 million for the nine months ended September 30, 2025, compared to $66.0 million for the nine months ended September 30, 2024. Cash generated by operating activities, other than changes in working capital, was higher by $5.9 million during the nine months ended September 30, 2025, as compared to the same period in the prior year primarily due higher earnings exclusive of non-cash expenses. The increase in cash from working capital during the nine months ended September 30, 2025 of $5.6 million was favorable compared to the nine months ended September 30, 2024 primarily due to favorable changes in accounts payable and accrued liabilities, partially offset by unfavorable changes in receivables.

The favorable change in accounts payable was due to the timing of vendor payments. The favorable change in accrued liabilities mainly relates to the timing of payments for interest and other expenses. The unfavorable change in receivables was driven by the timing of collection of sales.

Net cash used in investing activities was $92.9 million for the nine months ended September 30, 2025, compared to $43.0 million during the same period in 2024. Net cash used in investing activities primarily consisted of $51.6 million and $43.0 million to fund capital expenditures during the nine months ended September 30, 2025 and 2024, respectively. During the nine months ended September 30, 2025, we acquired the sulfuric acid production assets of Cornerstone Chemical Company LLC located at Waggaman, Louisiana for $41.3 million.

Net cash used in financing activities was $35.1 million for the nine months ended September 30, 2025, compared to $12.7 million during the same period in 2024. The unfavorable change in net cash used in financing activities was primarily driven by higher repurchases of the Company's common stock during the during the nine months ended September 30, 2025.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

***Debt***

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| | **(in millions)** | **(in millions)** |
| 2025 Term Loan Facility | $864.3 | $870.8 |
| ABL Facility |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total debt | 864.3 | 870.8 |
| Original issue discount | (6.5) | (7.2) |
| Deferred financing costs | (3.0) | (2.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total debt, net of original issue discount and deferred financing costs | 854.8 | 860.8 |
| Less: current portion | (8.7) | (8.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt, excluding current portion | $846.1 | $852.1 |

---

As of September 30, 2025, our total debt was $864.3 million, excluding the original issue discount of $6.5 million and deferred financing costs of $3.0 million for our senior secured credit facilities. Our net debt as of September 30, 2025 was $782.3 million, which reflects our total debt less cash and cash equivalents of $82.0 million. We may seek, subject to market conditions and other factors, opportunities to repurchase, refinance or otherwise reprice our debt.

***Capital Expenditures***

Maintenance capital expenditures include spending on maintenance of business, health, safety and environmental initiatives. Growth capital expenditures include spending to drive organic sales growth and cost savings initiatives. These capital expenditures represent our "book" capital expenditures for which the Company has recorded, but not necessarily paid for the capital expenditures.

---

| | | |
|:---|:---|:---|
| | **Nine months ended<br>September 30,** | **Nine months ended<br>September 30,** |
| | **2025** | **2024** |
| | **(in millions)** | **(in millions)** |
| Maintenance capital expenditures | $44.6 | $37.7 |
| Growth capital expenditures | 5.1 | 4.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total capital expenditures | $49.7 | $42.5 |

---

Capital expenditures remained at a level sufficient for required maintenance and certain expansion growth initiatives during these periods. Maintenance capital expenditures were higher in the nine months ended September 30, 2025, compared to the nine months ended September 30, 2024 due to turnaround activities in 2025.

**Critical Accounting Policies and Estimates**

We prepare our condensed consolidated financial statements in conformity with GAAP and our significant accounting policies are described in Note 2 to our audited consolidated financial statements included in our Annual Report on Form 10-K. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We base our estimates and judgments on historical experience and other relevant factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While there has been no material change in our critical accounting policies and use of estimates from those described in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," included in our Annual Report on Form 10-K, we continually evaluate our critical accounting estimates, assumptions and judgments on an ongoing basis. The Company completes its annual goodwill and indefinite-lived intangible assets impairment test during the fourth quarter of each year, or more frequently if triggering events indicate a possible impairment. The Company determines the fair value of its reporting units using both a market approach and an income, or discounted cash flow, approach. As of October 1, 2024, the date of the Company's most recent quantitative assessments, the fair values of each of the Company's reporting unit and the fair values of the Company's indefinite-lived trade names and trademarks exceeded their respective carrying values.

During the nine months ended September 30, 2025, the Company did not identify any events or circumstances that would more likely than not reduce the fair value of the Company's reporting units or intangible assets below their respective carrying values.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**Accounting Standards Not Yet Adopted**

See Note 2 to our unaudited condensed consolidated financial statements for a discussion of recently issued accounting standards and their effect on us.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

Our major market risk exposure is potential losses arising from changing rates and prices regarding foreign currency exchange rate risk, interest rate risk and credit risk. The audit committee of our Board regularly reviews foreign exchange and interest rate activity, and monitors compliance with our hedging policy. We do not use financial instruments for speculative purposes, and we limit our hedging activity to the underlying economic exposure.

There have been no material changes in the foreign currency exchange rate risk, interest rate risk or credit risk discussed in Item 7A., "Quantitative and Qualitative Disclosures about Market Risk," included in our Annual Report on Form 10-K.

**ITEM 4.&nbsp;&nbsp;&nbsp;&nbsp;CONTROLS AND PROCEDURES.**

***Evaluation of Disclosure Controls and Procedures***

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2025, the end of the period covered by this Quarterly Report on Form 10-Q.

The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act"), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective due to the material weakness in the Company's internal control over financial reporting, as described below and in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Notwithstanding the conclusion that the Company's disclosure controls and procedures were not effective as of September 30, 2025, our Chief Executive Officer and Chief Financial Officer believe that the Company's unaudited condensed consolidated financial statements included in this Quarterly Report are fairly stated in all material respects in accordance with U.S. generally accepted accounting principles for each of the periods presented.

***Material Weakness in Internal Control over Financial Reporting***

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis.

A material weakness in relation to the Company's controls over the accounting of its Zeolyst Joint Venture was identified as of December 31, 2024 and continues to exist as of September 30, 2025. The Company does not have sufficient controls designed to ensure its proportionate share of the earnings from the Zeolyst Joint Venture, an equity method investee underlying the Company's financial statements, were completely, accurately, and timely recorded. This material weakness resulted in immaterial adjustments to our equity in net income from affiliated companies and investments in affiliated companies as of and for the fiscal years ended December 31, 2024, 2023 and 2022, and for the interim periods contained within those fiscal years. This material weakness could result in a material misstatement of our equity in net income from affiliated companies and investments in affiliated companies that would not be prevented or detected on a timely basis.

***Plan for Remediation of Material Weakness***

We commenced a remediation plan with respect to this material weakness. In carrying out our plan, management modified existing key controls and implemented new key controls to ensure our proportionate share of the earnings from the Zeolyst Joint Venture are completely, accurately, and timely recorded in our financial statements. This material weakness will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We expect that the material weakness will be remediated before the end of 2025.

***Changes in Internal Control Over Financial Reporting***

No changes in our internal control over financial reporting occurred during the quarter ended September 30, 2025 that materially affected, or which are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**PART II**—**OTHER INFORMATION**

**ITEM 1.&nbsp;&nbsp;&nbsp;&nbsp;LEGAL PROCEEDINGS.**

From time to time, we may be subject to various legal claims and proceedings incidental to the normal conduct of business, relating to such matters as personal injury, product liability and warranty claims, waste disposal practices, release of chemicals into the environment and other matters that may arise in the ordinary course of our business. We currently believe that there is no litigation pending that is likely to have a material adverse effect on our business. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

**ITEM 1A.&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS.**

"Item 1A, Risk Factors" in our Annual Report on Form 10-K includes a discussion of our risk factors. There have been no material changes from the risk factors described in our Annual Report on Form 10-K.

**ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.**

The following table contains information about purchases of our common stock, excluding excise tax, during the third quarter of 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Total number of shares of common stock purchased**<sup>(1)</sup> | **Average price paid per share of common stock** <sup>(2)</sup> | **Total number of shares of common stock purchased as part of publicly announced plan or programs** | **Maximum number (or dollar value) of shares of common stock that may yet be purchased under the plans or programs (in thousands)**<sup>(1)</sup> |
| July 1, 2025—July 31, 2025 | 69695 | $7.64 | 69695 | $207202 |
| August 1, 2025—August 31, 2025 |  | $— |  | $207202 |
| September 1, 2025—September 30, 2025 | 540517 | $9.24 | 540517 | $202207 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | 610212 |  |  |  |

---

<sup>(1)</sup> In April 2022, our Board approved and announced a new stock repurchase program authorizing the repurchase of up to $450 million of the Company's outstanding common stock over the next four years. This program is expected to be funded using cash on hand and cash generated from operations. For possible future repurchases, the actual timing, number, and nature of shares repurchased will depend on a variety of factors, including stock price, trading volume, and general business and market conditions and may be conducted through negotiated transactions, open market repurchases or other means, including through Rule 10b-18 and 10b5-1 trading plans or accelerated share repurchases. The repurchase program does not obligate us to acquire any number of shares in any specific period or at all and may be amended, suspended or discontinued at any time at our discretion.

During the three months ended September 30, 2025, the Company purchased 610,212 shares of its common stock on the open market pursuant to the stock repurchase program, for a total cost of $5.5 million. As of September 30, 2025, $202.2 million was available for share repurchases under the program.

<sup>(2)</sup> Excludes brokerage commissions and other costs of execution.

**ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;OTHER INFORMATION.**

***Trading Arrangements***

During the three months ended September 30, 2025, none of the Company's directors or executive officers adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," each as defined in Item 408(a) of Regulation S-K.

***Share Repurchase Program Modification***

On October 30, 2025, our Board amended our Stock Repurchase Program to remove the limitation that all repurchases must be made within the four-year period from the date of original approval on April 27, 2022.

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS.**

The following exhibits are being filed or furnished as part of this Quarterly Report on Form 10-Q:

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| 2.1 | <u>[Stock Purchase Agreement, dated as of September 10, 2025, by and between Ecovyst Inc. and Technip Energies N.V. (incorporated by reference to Exhibit 2.1 to the Company's Form 8-K, filed September 11, 2025)](https://www.sec.gov/Archives/edgar/data/1708035/000119312525201371/d897813dex21.htm)</u> |
| 10.1\* | <u>[Transition Agreement and General Release,](ex101-transitionagreementa.htm)[effective](ex101-transitionagreementa.htm)[as of August 11, 2025, between Ecovyst Inc. and George L. Vann, Jr.](ex101-transitionagreementa.htm)</u> |
| 31.1 | <u>[Certification of Chief Executive Officer of Ecovyst Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex311-sec302ceocertx093020.htm)</u> |
| 31.2 | <u>[Certification of Chief Financial Officer of Ecovyst Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex312-sec302cfocertx093020.htm)</u> |
| 32.1 | <u>[Certification of Chief Executive Officer of Ecovyst Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex321-sec906ceocertx093020.htm)</u> |
| 32.2 | <u>[Certification of Chief Financial Officer of Ecovyst Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex322-sec906cfocertx093020.htm)</u> |
| 101 | The following materials from the Quarterly Report on Form 10-Q of Ecovyst Inc. for the quarter ended September 30, 2025, formatted in Inline XBRL: (i) Condensed Consolidated Statements of (Loss) Income, (ii) Condensed Consolidated Statements of Comprehensive (Loss) Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Stockholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, (vi) Notes to Condensed Consolidated Financial Statements and (vii) document and entity information, tagged as blocks of text and including detailed tags |
| 104 | The cover page from the Quarterly Report on Form 10-Q of Ecovyst Inc. for the quarter ended September 30, 2025, formatted in Inline XBRL and included as Exhibit 101 |

---

\* Management contract or compensatory plan

------

<u>[Table of](#iddb748d90dea449ba1f5857845b24cb5_7)[Contents](#iddb748d90dea449ba1f5857845b24cb5_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **Ecovyst Inc.** |
| &nbsp;&nbsp;Date: | November 5, 2025 | By: | /s/ MICHAEL FEEHAN |
|  |  |  | Michael Feehan |
|  |  |  | Vice President and Chief Financial Officer |
|  |  |  | (Duly Authorized Officer and Principal Financial and Accounting Officer) |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>PLEASE READ CAREFULLY. THIS TRANSITION AGREEMENT AND GENERAL RELEASE INCLUDES A RELEASE OF KNOWN AND UNKNOWN CLAIMS.</u>**

**<u>TRANSITION AGREEMENT AND GENERAL RELEASE</u>**

This Transition Agreement and General Release ("Agreement"), is entered into by and between Eco Services Operations Corp., a Delaware corporation (the "Company"), that is a wholly-owned subsidiary of Ecovyst Inc. ("Ecovyst"), and George L. Vann, Jr. ("Mr. Vann"), his heirs, executors, administrators, successors, and assigns.

**WHEREAS**, the Company has determined that Mr. Vann's employment will end on the Separation Date set forth below, and both the Company and Mr. Vann and the Company mutually desire to amicably conclude his employment relationship; and

**WHEREAS**, Mr. Vann certifies that he has had a reasonable opportunity of at least twenty-one (21) days to consider this Agreement and consult an attorney of his choice to decide whether to sign it; and

**WHEREAS**, Mr. Vann has carefully read and fully understands all of the provisions and effects of this Agreement.

**NOW, THEREFORE**, Mr. Vann and the Company, for the good and sufficient consideration set forth below, and intending to be legally bound hereby, agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.**<u>Separation Date</u>**. Mr. Vann's employment with the Company will end effective August 11, 2025 ("Separation Date").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.**<u>Accrued Wages and Vacation Pay</u>**. Mr. Vann acknowledges that he will receive payment for all wages owed and for accrued but unused vacation through the Separation Date. These amounts will be paid by the Company pursuant to the timing and other processes applicable to regular payroll, but no later than six days after the Separation Date. Except as set forth in this Agreement, Mr. Vann's eligibility to participate in any insurance or other employee benefits provided by the Company will cease on the Separation Date; provided, however, that it is acknowledged and agreed that Mr. Vann's health insurance benefits will continue through the end of August 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.**<u>Consideration</u>**. In consideration for the signing of this Agreement and Mr. Vann's adherence to the promises made herein, and payable beginning no later than the day that is forty-five (45) days following the Separation Date subject to this Agreement being made effective as set forth in Paragraph 18 below, the Company agrees to provide Mr. Vann the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Two weeks' pay in lieu of notice, less applicable taxes and other normal withholdings, to be paid on the next payroll date following the effective date of this Agreement as described in Section 18 hereof.

&nbsp;&nbsp;&nbsp;&nbsp;1

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)From the Separation Date and continuing for a period of 58 weeks (such period, the "Severance Period"), the Company will pay Mr. Vann an amount equal to his current base salary of $390,000 plus his annual cash incentive bonus at target (60% of base salary), less applicable taxes and withholdings, in accordance with the Company's regular payroll practices, and via direct deposit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)During the Severance Period and if Mr. Vann makes a timely election of health benefits under the Consolidated Omnibus Budget Reconciliation Act ("COBRA") benefits, the Company will pay an amount equal to its applicable share of the premium costs to continue Mr. Vann's current level of coverage under the Company's health plans. However, Mr. Vann shall be required to pay all premiums and other costs for such coverage as is generally applicable to the Company's then-active employees, and such amounts shall be deducted from the Severance Period payments made pursuant to Section 3(b) hereof. The Company will continue to pay the foregoing premium costs unless Mr. Vann finds employment that offers substantially equivalent health coverage prior to the expiration of the Severance Period, at which time the Company will cease paying any portion of Mr. Vann's premiums. Mr. Vann shall provide notice of any such employment and health coverage to the Company promptly after obtaining such employment and medical coverage.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Mr. Vann will be paid a prorated portion of the 2025 annual cash incentive performance bonus that may be earned based on achievement, if any, of the performance metrics applicable thereto (the "2025 Bonus"), such amount to be prorated based on the period of time Mr. Vann was employed by the Company in 2025. The prorated 2025 Bonus shall be paid at the same time as the 2025 Bonus is paid to eligible Company employees but in any event no later than March 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.**<u>No Consideration Absent Execution of this Agreement</u>**. Mr. Vann understands and agrees that the consideration offered in Paragraph 3 above is additional to anything that is owed to him, and that he would not receive the consideration specified except for his execution of this Agreement and the fulfillment of the promises contained herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.**<u>Current Equity Interests</u>**. Mr. Vann understands that any Ecovyst equity awards that were granted are subject to the relevant equity incentive plan and the applicable agreements (including, but not limited to, Restricted Stock Unit ("RSU") Agreements and/or Performance Stock Unit ("PSU") Agreements) that he executed, and that (i) any unvested Ecovyst RSUs will not be eligible for vesting pursuant to the applicable plan documents and agreements, and (ii) any unvested Ecovyst PSUs will be eligible for vesting, on a pro-rata basis as described in the applicable plan documents and agreements, if the applicable performance metrics are satisfied with respect to such PSUs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.**<u>General Release of Claims</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Mr. Vann knowingly and voluntarily releases and forever discharges the Company and its parents, wholly or partially owned subsidiaries, affiliates, divisions, predecessor companies, successors and assigns (specifically including, for the avoidance of doubt, Ecovyst Catalyst Technologies LLC and Chem32 LLC) (collectively, the "Ecovyst Companies"), and its and their current and former employees, attorneys, shareholders, members, officers, directors and agents thereof, and the current and former trustees or administrators of any pension or other benefit plan applicable to the employees or former employees of any of the

&nbsp;&nbsp;&nbsp;&nbsp;2

------

Ecovyst Companies (collectively referred to throughout the remainder of this Agreement as "Releasees"), of and from any and all claims, demands, liabilities, obligations, promises, controversies, damages, rights, actions and causes of action, known and unknown, which Mr. Vann has or may have against the Releasees as of the date of execution of this Agreement, including, but not limited to, any alleged violation of: Title VII of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; the Americans with Disabilities Act of 1990, as amended; the Age Discrimination in Employment Act of 1967, as amended; the Older Workers Benefit Protection Act; any and all claims arising under the Texas Labor Code, including the Texas Payday Act, the Texas Anti-Retaliation Act, Chapter 21 of the Texas Labor Code, the Texas Whistleblower Act, and all including any amendments and their respective implementing regulations; or any other federal, state or local civil or human rights law or any other local or state public policy, or under any other theory of contract, tort, or common law; or for any allegation for costs, fees, or other expenses including attorneys' fees (all of the above collectively referred to as "Claims").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)This release is intended to be a general release and includes Claims arising from Mr. Vann's employment or separation of employment from the Company, up to and through the date Mr. Vann signs this Agreement, and excludes only those Claims that Mr. Vann is legally barred from releasing. Mr. Vann understands that the release does not include, and the parties hereto expressly reserve, any Claim that cannot be released or waived as a matter of law; any Claim for or right to vested benefits under the Company' plans, including, but not limited to, any pension or retirement account, or any right to enforce any term of this Agreement. The parties further exclude any challenge to the validity of the Agreement; or any prohibition on the filing of a charge or complaint with, or testimony, assistance or participation in, any investigation, proceeding or hearing conducted by any federal, state or local governmental agency, including but not limited to the Equal Employment Opportunity Commission.

**Mr. Vann has been advised to contact independent legal counsel to ensure that he understands the scope of this release.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.**<u>Affirmations</u>**. Mr. Vann represents and agrees by signing below that he has not been denied any legally entitled leave or benefit requested, has received the appropriate pay for all hours worked for the Company, and has no known workplace injuries or occupational diseases. Other than the consideration set forth in Paragraph 3, Mr. Vann further affirms that he has been paid and/or has received all leave (paid or unpaid, including vacation), compensation, wages, bonuses and/or commissions to which he may have been entitled and that no other leave (paid or unpaid), compensation, wages, bonuses and/or commissions are due to him, except as provided in this Agreement.

Mr. Vann affirms he has neither filed, nor caused or permitted to be filed on his behalf any lawsuit, complaint, proceeding or action before any court against the Company, and that no such charge, complaint, proceeding or action exists to his knowledge. If any administrative agency or court assumes jurisdiction of any charge, complaint, proceeding or action, including a Claim released in Paragraph 6 above, Mr. Vann agrees not to accept, recover or receive any

&nbsp;&nbsp;&nbsp;&nbsp;3

------

monetary damages or other relief from or in connection with such charge, complaint, proceeding or action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.**<u>Return of Property</u>**. On or before the Separation Date, Mr. Vann will return to the Company all property and information belonging to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.**<u>Certain Agreements.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Nondisclosure and Nonuse of Confidential Information</u>. From and after the Separation Date, Mr. Vann will not disclose or use at any time any trade secrets or Confidential Information of any of the Ecovyst Companies, except to the extent that (i) such disclosure is required in connection with any action by Mr. Vann to enforce rights under this Agreement or (iii) such disclosure is required by a court of law, governmental agency, or by any administrative or legislative body with jurisdiction to order Mr. Vann to divulge or disclose such Confidential Information; <u>provided</u>, that, Mr. Vann shall provide ten (10) days prior written notice to the Company of any such requirement or order to disclose Confidential Information so that the Company may seek a protective order or similar remedy; and, provided, further, that, in each case set forth above, Mr. Vann informs the recipients that such information or communication is confidential in nature. In addition, nothing in this Agreement limits, restricts or in any other way affects Mr. Vann's communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity. Mr. Vann cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (a) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or (b) in a complaint or other document filed under seal in a lawsuit or other proceeding. Notwithstanding this immunity from liability, Mr. Vann may be held liable if Mr. Vann has unlawfully accessed trade secrets by unauthorized means. For the purposes of this Agreement, "Confidential Information" shall mean information that is not generally known to the public and that is or was used, developed or obtained by Ecovyst, the Company, or any of their Affiliates, including, but not limited to the following: (i) information, observations, procedures and data known by Mr. Vann as a consequence of his employment with, or direct or indirect services as agent, employee or consultant, to or on behalf of, the Company or Ecovyst or any Affiliates of either of them concerning the business or affairs of Ecovyst, the Company or any of their Affiliates; (ii) products or services; (iii) costs and pricing structures; (iv) analyses; (v) drawings, photographs and reports; (vi) computer software, including operating systems, applications and program listings; (vii) flow charts, manuals and documentation; (viii) data bases; (ix) accounting and business methods; (x) inventions, devices, new developments, methods and processes, whether patentable or unpatentable and whether or not reduced to practice; (xi) customers, vendors, suppliers and customer, vendor and supplier lists; (xii) other copyrightable works; (xiii) all production methods, processes, technology and trade secrets and (xiv) all similar and related information in whatever form. "Trade Secrets" shall mean information belonging to one or more of the Ecovyst Entities, without regard to form, including, but not limited to, technical or non-technical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans, strategic or other business plans or proposals, or a list of actual or potential customers or suppliers, which is not commonly known by or available to the public and which information (xv) derives economic value, actual or potential, from not being generally known to and not being readily ascertainable by proper means by other persons who can obtain economic value from its disclosure or use; and (xvi) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. Trade Secrets also shall include, without limitation, any information described in this subsection 8(a)(i) which one or more of the Ecovyst Entities obtains from another party which the Ecovyst Entity

&nbsp;&nbsp;&nbsp;&nbsp;4

------

treats as proprietary or designates as Trade Secrets, whether owned or developed by one or more of the Ecovyst Entities. Confidential Information will not include any information that has been published in a form generally available to the public prior to the date Mr. Vann proposes to disclose or use such information. Confidential Information will not be deemed to have been published merely because individual portions of the information have been separately published, but only if all material features comprising such information have been published in combination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The intent of Section 9(a) is to provide the Ecovyst Entities with the broadest possible remedies afforded to it under applicable law, including, but not limited to, those remedies available under the Federal Defend Trade Secrets Act, as may be amended. Notwithstanding any other provision of this Agreement, for the avoidance of doubt, nothing herein prevents reporting possible violations of federal law or regulation to any governmental agency or entity, or making other disclosures, protected under the whistleblower provisions of federal law or regulation ("Lawful Reporting"). Further, nothing in this Agreement prohibits Mr. Vann's disclosure of Confidential Information (including Trade Secrets) in confidence when it is solely for Lawful Reporting to a governmental authority or Physician's legal counsel to address possible legal violations, or if required to do so by law. However, any disclosure of Confidential Information must be in good faith and effectuated to prevent the dissemination of such Confidential Information beyond those persons necessary to make the report or filing, such as filing the Confidential Information under seal and otherwise preventing it from becoming generally known. Any disclosure of trade secrets must be consistent with 18 U.S.C. §1833 to avoid prosecution or liability

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Inventions and Patents</u>. Mr. Vann agrees that all Work Product belongs to the Company. Mr. Vann will promptly disclose such Work Product to the Company and perform all actions reasonably requested by the Company to establish and confirm such ownership (including, without limitation, the execution and delivery of assignments, consents, powers of attorney and other instruments) and to provide reasonable assistance to the Company in connection with the prosecution of any applications for patents, trademarks, trade names, service marks or reissues thereof or in the prosecution or defense of interferences relating to any Work Product. For the purposes of this Agreement, "Work Product" shall mean all inventions, innovations, improvements, technical information, systems, software developments, methods, designs, analyses, drawings, reports, service marks, trademarks, tradenames, logos and all similar or related information (whether patentable or unpatentable) which relates to the Company's, Ecovyst's or any of its or their Affiliates' actual or anticipated business, research and development or existing or future products or services and which were conceived, developed or made by Mr. Vann (whether or not during usual business hours and whether or not alone or in conjunction with any other Person) while employed by the Company together with all patent applications, letters patent, trademark, tradename and service mark applications or registrations, copyrights and reissues thereof that may be granted for or upon any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Compete and Non-Solicitation</u>. Mr. Vann acknowledges and agrees with the Company that during the course of Mr. Vann's employment with the Company, Mr. Vann had access to the Ecovyst's and the Company's Confidential Information and trade secrets, as defined above, and had the opportunity to develop relationships with existing employees, customers and other business associates of Ecovyst, the Company and/or their Affiliates (collectively, the "Ecovyst Entities") which Confidential Information, trade secrets and relationships exist throughout the world and constitute goodwill of one or more of the Ecovyst Entities, and the Ecovyst Entities would be irreparably damaged if Mr. Vann were to take actions that would damage or misappropriate such goodwill. Accordingly, Mr. Vann agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;5

------

&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;Mr. Vann acknowledges that the Ecovyst Entities currently conduct their businesses throughout the world (the "Territory"). Accordingly, during the 24-month period following the Separation Date (the "Non-Compete Period"), Mr. Vann shall not, directly or indirectly, enter into, engage in, assist, give or lend funds to or otherwise finance, be employed by or consult with, or have a financial or other interest in, any Person that offers one or more products or services or engages in a business, in each case, that is directly competitive with a product or service or the business of the Ecovyst Entities, as conducted or in active planning (a "Competitor"), whether for or by himself or in any other capacity. For the purposes of this Agreement, the term "Person" shall be construed broadly and shall include, without limitation, an individual, a partnership, an investment fund, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. To the extent that the covenant provided for in this section may later be deemed by a court to be too broad to be enforced with respect to its duration or with respect to any particular activity or geographic area, the court making such determination shall have the power to reduce the duration or scope of the provision, and to add or delete specific words or phrases to or from the provision. The provision as modified shall then be enforced. Notwithstanding the foregoing restriction, it shall not be a violation of this section for Mr. Vann to work for a Competitor if: (i) Mr. Vann works in a separate legal subsidiary or Affiliate that offers products or services or conducts a business, in each case, that is not directly competitive with the Ecovyst Entities, (ii) Mr. Vann informs Ecovyst in writing prior to accepting the position how such position complies with the terms of this subsection, and (iii) Ecovyst consents to Mr. Vann's employment with such entity, which consent shall not be unreasonably withheld.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, the aggregate ownership by Mr. Vann of no more than two percent (on a fully-diluted basis) of the outstanding equity securities of any Person, which securities are traded on a national or foreign securities exchange, quoted on the NASDAQ stock market or other automated quotation system, and which Person competes with the Ecovyst Entities (or any part thereof) within the Territory, shall not be deemed to be a violation of this Section 9(c). In the event that any Person in which Mr. Vann has any financial or other interest directly or indirectly enters into a line of business during the Non-Compete Period that competes with the Ecovyst Entities or engages in the business of the Ecovyst Entities within the Territory, Mr. Vann shall divest all of his interest (other than as permitted to be held pursuant to the first sentence of this Section 9(c)(ii) in such Person within 15 days after such Person enters into such line of business that competes with the Ecovyst Entities or engages in such business within the Territory; provided that, in the event that such equity interest is not publicly traded, Mr. Vann will divest such interest as promptly as practicable and, pending such divestiture, will recuse himself from any and all activities that would be in competition, whether directly or indirectly, with the Ecovyst Entities or that would otherwise be precluded under this Section 9(c). For the avoidance of doubt, the immediately preceding sentence shall not be construed as an amendment, waiver or modification to any other term or provision of this Agreement, or to any restrictive covenant or other provision contained in any agreement between Mr. Vann, Ecovyst, the Company or any Affiliate of any of them.

&nbsp;&nbsp;&nbsp;&nbsp;6

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;&nbsp;&nbsp;Mr. Vann covenants and agrees that during the 24-month period following the Separation Date, except as expressly provided herein, Mr. Vann will not, directly or indirectly, either for himself or for any other Person (i) solicit or attempt to induce any employee or consultant of the Ecovyst Entities to terminate his or her employment or relationship; (ii) employ any employee or consultant of the Ecovyst Entities during the period of his or her employment or consulting relationship with the Ecovyst Entities; (iii) solicit any customer of the Ecovyst Entities to purchase or distribute information, products or services of or on behalf of Mr. Vann or such other Person that are competitive with the information, products or services provided by the Ecovyst Entities or (iv) take any action that may cause injury to or interfere with the relationships between the Ecovyst Entities or any of their employees and any lessor, lessee, vendor, supplier, customer, distributor, employee, consultant or other business associate of the Ecovyst Entities as such relationship relates to the Ecovyst Entities' conduct of their businesses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;&nbsp;&nbsp;Mr. Vann understands that the foregoing restrictions may limit his ability to earn a livelihood in a business similar to the businesses of the Ecovyst Entities. However, based on the position he held with the Company he agrees that that restrictions are reasonable, and that he has received and will receive sufficient consideration and other benefits as an employee of the Company and as otherwise provided hereunder to clearly justify such restrictions which, in any event (given his education, skills and ability), Mr. Vann does not believe would prevent him from otherwise earning a living.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.**<u>No Disparagement</u>**. Mr. Vann has not from the date Mr. Vann was given this Agreement and will not in the future make any defamatory or disparaging statements to any third parties regarding the Ecovyst Entities, or any of their employees, officers, or board members, as well as the products, services and methods of operations of the Ecovyst Entities. Notwithstanding the foregoing, this Agreement does not prohibit Mr. Vann from (a) providing truthful testimony in response to compulsory legal process, (b) participating or assisting in any investigation or inquiry by a governmental agency acting within the scope of its statutory or regulatory jurisdiction, or (c) making truthful statements in connection with any claim permitted to be brought by Mr. Vann hereunder. In addition, nothing in this Agreement limits, restricts or in any other way affects Mr. Vann's communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.**<u>Cooperation</u>.** Mr. Vann will (i) cooperate with the Company in all reasonable respects concerning any transitional matters which require Mr. Vann's assistance, cooperation or knowledge, including communicating with persons inside or outside the Company as directed by the Company, and (ii) in the event that the Company (or any of its affiliates or other related entities) becomes involved in any legal action relating to events which occurred during Mr. Vann's employment with the Company, cooperate to the fullest extent possible in the preparation, prosecution or defense of their case, including, but not limited to, the execution of affidavits or documents, testifying or providing information requested by the Company. To the extent that Mr. Vann incurs (i) travel-related expenses, (ii) out-of-pocket expenses, and/or (iii) loss of wages as a result of Mr. Vann's cooperation with the Company as contemplated by this

&nbsp;&nbsp;&nbsp;&nbsp;7

------

Section, the Company will reimburse Executive for such expenses, provided they are reasonable and were approved by the Company in advance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.**<u>Governing Law and Interpretation</u>**. This Agreement shall be governed by and construed in accordance with the laws of the State of Texas without regard to conflict of laws provisions or any provision that would render applicable another jurisdiction's substantive law in any dispute.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.**<u>Severability</u>**. If any term, provision or paragraph of this Agreement is determined by a court of competent jurisdiction to be invalid or unenforceable for any reason, such determination shall be limited to the narrowest possible scope in order to preserve the enforceability of the remaining portions of the term, provision or paragraph, and such determination shall not affect the remaining terms, provisions or paragraphs of this Agreement, which shall continue to be given full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.**<u>No Admission of Wrongdoing</u>**. The parties agree that neither this Agreement nor the furnishing of the consideration for this Agreement shall be deemed or construed at any time for any purpose as an admission by either of the parties, or evidence of any liability or unlawful conduct of any kind.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.**<u>Code Section 409A</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)It is intended that the payments and benefits provided under this Agreement shall be exempt from or comply with the application of the requirements of Code Section 409A, and this Agreement shall be construed and administered in a manner that affects such intent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)For purposes of Code Section 409A, each payment made under this Agreement is intended to be a separate payment. Any taxable benefits or payments provided under the Agreement are intended to qualify for the "short-term deferral" exception to Code Section 409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the separation (severance) pay exceptions to Code Section 409A, to the maximum extent possible. To the extent that none of these exceptions (or any other available exception) applies, then notwithstanding anything contained herein to the contrary, and to the extent required to comply with Code Section 409A, if Mr. Vann is a "specified employee," as determined by the Company in accordance with Code Section 409A, as of the Separation Date, then all amounts due under the Agreement that constitute a "deferral of compensation" within the meaning of Code Section 409A, that are provided as a result of a "separation from service" within the meaning of Code Section 409A, and that would otherwise be paid or provided during the first six months following the Separation Date, shall be accumulated through and paid or provided on the first business day that is more than six months after the date of the Separation Date (or, if the Mr. Vann dies during such six-month period, within 90 days after Mr. Vann's death). In no event shall Mr. Vann be permitted, directly or indirectly, to designate the taxable year of payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code Section 409A: (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit; (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any calendar year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; and (iii) such payments shall be made on or before the last day of the calendar year following the calendar year in which the expense

&nbsp;&nbsp;&nbsp;&nbsp;8

------

occurred, or such earlier date as required hereunder. The payments and benefits provided under the Agreement may not be deferred, accelerated, extended, paid out or modified in a manner that would result in the imposition of an additional tax, interest, penalties or other monetary amounts under Code Section 409A upon Mr. Vann. Although the Company will use its best efforts to avoid the imposition of taxation, interest, penalties or other monetary amounts under Section 409A of the Code, the tax treatment of the benefits provided under the Agreement is not warranted or guaranteed. None of the Ecovyst Companies or their respective directors, officers, executives or advisers shall be held liable for any taxes, interest, penalties or other monetary amounts owed by Mr. Vann (or any other individual claiming a benefit through Mr. Vann) as a result of the Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.**<u>Entire Agreement/Amendment</u>**. No prior or contemporaneous oral or written agreements or representations may be offered to alter the terms of this Agreement which represents the entire agreement of the parties with respect to the subject matter hereof. This Agreement may not be modified, altered or changed except in writing and signed by both parties wherein specific reference is made to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.**<u>Signatures</u>**. This Agreement may be executed in counterparts, any such copy of which to be deemed an original, including signatures sent via pdf or facsimile, but all of which together shall constitute the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.**<u>Revocation and Effective Date</u>**. Mr. Vann agrees that he received this Agreement on August 11, 2025 and also agrees and understands that he has 21 days from the date he receives that date to sign it. Any changes to the Agreement, regardless of whether they are material, will not extend the twenty-one (21) day period. In addition, for a period of seven (7) days following the execution date of this Agreement, he may revoke this Agreement and it shall not become effective and enforceable until the eighth (8th) day following the Agreement being fully executed as indicated below. Any such revocation must be in writing and correctly postmarked or delivered to Kara L. Thornton, Ecovyst Inc., P.O. Box 834, Valley Forge, PA 19482, within seven (7) days of Mr. Vann's signing this Agreement to be effective. If Mr. Vann does so revoke, this Agreement shall be null and void, and the Company shall have no obligation to provide or pay any of the compensation or benefits described in Paragraph 3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.**<u>Resignation as Officer and Director</u>**. By signing this Agreement, Mr. Vann resigns, effective as of the Separation Date, each and every officer and director position that Mr. Vann holds with any Ecovyst Company. Upon request from the Company, Mr. Vann shall execute and deliver any separate confirmatory resignation(s) from officer and director positions as the Company deems to be necessary or desirable.

**[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]**

&nbsp;&nbsp;&nbsp;&nbsp;9

------

IN WITNESS WHEREOF, the parties hereto knowingly and voluntarily executed this Agreement as of the date set forth below:

**ECO SERVICES OPERATIONS CORP.** 

B: <u>/s/ Kara L. Thornton&nbsp;&nbsp;&nbsp;&nbsp;</u>

Kara L. Thornton, Chief Human Resources Officer

Date: <u>August 25, 2025&nbsp;&nbsp;&nbsp;&nbsp;</u>

<u>/s/ George L. Vann, Jr.&nbsp;&nbsp;&nbsp;&nbsp;</u>

George L. Vann, Jr.

Date: <u>August 21, 2025&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;10

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER** 

**PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Kurt J. Bitting, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ecovyst Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | November 5, 2025 | /s/ KURT J. BITTING |
| | | Kurt J. Bitting |
| | | Chief Executive Officer |
| | | (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Michael Feehan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ecovyst Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | November 5, 2025 | /s/ MICHAEL FEEHAN |
| | | Michael Feehan |
| | | Vice President and Chief Financial Officer |
| | | (Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Ecovyst Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kurt J. Bitting, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: | November 5, 2025 | /s/ KURT J. BITTING |
| | | Kurt J. Bitting |
| | | Chief Executive Officer |
| | | (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Ecovyst Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Michael Feehan, Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: | November 5, 2025 | /s/ MICHAEL FEEHAN |
| | | Michael Feehan |
| | | Vice President and Chief Financial Officer |
| | | (Principal Financial Officer) |

---

<br>